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Abstract 
Leucine-rich repeat and immunoglobulin domain-containing protein (Lingo-1) is a potent negative 
regulator of neuron and oligodendrocyte survival, neurite extension, axon regeneration, 
oligodendrocyte differentiation, axonal myelination and functional recovery; all processes highly 
implicated in numerous brain-related functions. Although playing a major role in developmental brain 
functions, the potential application of Lingo-1 as a therapeutic target for the treatment of neurological 
disorders has so far been under-estimated. A number of preclinical studies have shown that various 
methods of antagonizing Lingo-1 results in neuronal and oligodendroglial survival, axonal growth and 
remyelination; however to date literature has only detailed applications of Lingo-1 targeted 
therapeutics with a focus primarily on myelination disorders such as multiple sclerosis and spinal cord 
injury; omitting important information regarding Lingo-1 signaling co-factors. Here, we provide for 
the first time a complete and thorough review of the implications of Lingo-1 signaling in a wide range 
of neurological and psychiatric disorders, and critically examine its potential as a novel therapeutic 
target for these disorders. 
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1. Introduction 
Myelination is a fundamental progressive process occurring throughout the brain from embryonic 
stages of development through to adolescence. During the last decade, novel signaling pathways, 
largely involving myelin associated inhibitory proteins including: myelin associated glycoprotein 
(MAG), oligodendrocyte-myelin glycoprotein (OMgp) and neurite outgrowth inhibitor (Nogo) were 
found to inhibit the growth of neurons and myelination. Mechanisms involved in these processes 
largely implicate a receptor complex comprised of the p75 neurotrophin receptor and the (then) newly 
discovered Nogo Receptor (NgR) (Caroni and Schwab, 1988; Chen et al., 2000; Domeniconi et al., 
2002; Fournier et al., 2001; GrandPré et al., 2000; Liu et al., 2002; Kevin C. Wang et al., 2002a, 
2002b). The mechanism by which NgR regulates axonal growth is initiated by the high affinity 
binding of Nogo to the NgR, however the NgR itself does not contain a transmembrane domain and as 
such requires a transmembrane co-receptor in order to elicit intracellular signals. While p75 has been 
shown to elicit the transduction of inhibitory NgR signals (Kevin C. Wang et al., 2002a), certain NgR 
containing cell types not expressing p75, were still found to be able to transduce inhibitory NgR 
signals (Kevin C. Wang et al., 2002a), leading to the discovery of TNF receptor orphan Y (TROY) as 
a functional homolog of p75 within the signaling complex (Shao et al., 2005). The functional ternary 
receptor complex was suggested to be complete when a third co-receptor was discovered in the form 
of Lingo-1 (Leucine-rich repeat and Ig domain-containing, Nogo receptor-interacting protein) (Mi et 
al., 2004) and the Lingo-1/NgR/p75 or TROY complex was born. 
Lingo-1 was first identified as LERN1 (leucine-rich repeat neuronal protein 1), a transmembrane 
leucine-rich protein coded for by the novel gene LRRN6A discovered by Carim-Todd and 
collaborators (Carim-Todd et al., 2003) on human chromosome 15q24-26 just over a decade ago. It 
was suggested that due to the developmental expression profile of LRRN6A, the predicted protein 
structure of LERN1 and its similarity to proteins already identified as having a vital role in nervous 
system development and maintenance, that the LRRN6A gene and LERN1 protein would be highly 
relevant for further study in neurobiology. While a number of previously uncharacterized central 
nervous system-specific proteins were being assessed for their ability to bind to NgR, Lingo-1 was 
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discovered as we know it today, Leucine-rich repeat and Ig domain-containing, Nogo receptor-
interacting protein (Mi et al., 2004). Lingo-1 has been widely studied in relation to multiple sclerosis 
and spinal cord injury due to its prominent role in myelination and myelin related processes, however 
there has always been lack of information in relation to psychiatric disorders. Considering the ever 
growing evidence that the essential developmental functions of neurite outgrowth and myelination are 
disrupted in psychiatric disorders like schizophrenia, it seems timely and topical to consider the role 
of Lingo-1 in neuropsychiatric disorders. Here we provide a comprehensive review on Lingo-1, a 
relatively new candidate that since discovery has been studied across a wide range of neurological 
disorders, and why it is a promising candidate for future research in neuropsychiatric disorders and 
their therapeutic approaches. 
Note: For the purpose of this review, the terms LRRN6A and LERN1 will no longer be used and the 
gene and protein will be referred to as Lingo-1 and Lingo-1 respectively. 
2. Lingo-1: the Gene, Structure, Expression and Function 
The identification and characterization of the Lingo-1 gene (Carim-Todd et al., 2003) was an 
important first step to uncovering the function of Lingo-1. The Lingo-1 locus on human chromosome 
15q24-26 is a region that has been widely implicated in a number of psychiatric, addictive and anxiety 
related disorders, and genomic alterations in this chromosomic region are considered to be 
susceptibility factors for schizophrenia, depression, autism, panic disorders, anxiety and phobic 
disorders (Gratacòs et al., 2001; McInnes et al., 2010). 
The Lingo-1 gene maintains a very high degree of conservation across a large number of unrelated 
vertebrate species, including both mouse and rat (Carim-Todd et al., 2003). Furthermore, two 
additional paralogous genes have been mapped to human chromosomes 9 and 19 which were 
identified as LRRN6B and LRRN6C, coding for proteins LERN2 and LERN3 (Carim-Todd et al., 
2003) also known as Lingo-3 and Lingo-2 respectively (Chen et al., 2006). 
The Lingo-1 structure has been shown to be highly stable in a tetrameric conformation in both its 
crystal form and in solution, facilitated by its leucine-rich repeat-Ig-composite fold (Mosyak et al., 
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2006). Due to the tetramer burying such a large surface area into the cell membrane it is thought that 
this may in fact serve as an efficient and stable scaffold for a binding platform, facilitating the 
assembly of the Lingo-1/NgR/p75 or TROY complex, localizing signaling functions to the sites of 
neuronal pathways that terminate axon growth (Mosyak et al., 2006). Accordingly, knowing that 
Lingo-1 forms tetramers may provide an answer to the still unresolved questions about the 
stoichiometry of the Lingo-1/NgR/p75 or TROY receptor complex. It has been hypothesized that 
Lingo-1 may form tetramers relative to the monomers on the cell surface, meaning that each signaling 
complex may consist of four of each receptor component (4:4:4) rather than one (1:1:1) as previously 
thought. It is apparent that Lingo-1 is involved in a number of central nervous system processes, in 
addition to having the ability to bind a number of signaling molecules, thus its functional roles within 
the central nervous system and its mechanisms of oligomerization may vary depending on the where 
and when it is expressed (Mosyak et al., 2006). Just recently the crystalline tetrameric formation of 
Lingo-1 has been confirmed by Pepinsky et. al., in addition to showing for the first time that Lingo-1 
is also present as a tetramer on cells expressing full-length Lingo-1 (Pepinsky et al., 2014). This 
tetrameric formation on transfected cells is indicative of oligomer formation being an intrinsic 
property of Lingo-1 in the absence of its ligands or co-receptors (Pepinsky et al., 2014). 
Proteins containing leucine-rich repeats have been shown to play an important role in protein-protein 
interactions (Kajava et al., 1995; Kobe and Deisenhofer, 1994; Kobe and Kajava, 2001) in a wide 
variety of cellular processes (Carim-Todd et al., 2003) including ligand recognition (Brose et al., 
1999; Chen et al., 2001; Li et al., 1999; Vourc’h et al., 2003; Kevin C. Wang et al., 2002b). Their 
implication in important neurodevelopmental functions such as neuronal differentiation and growth 
(Halegoua et al., 1991) and the regulation of axon guidance, axon branching, cell-migration and 
regeneration processes (Bormann et al., 1999; Brose and Tessier-Lavigne, 2000; Ishii et al., 1996; 
Nguyen-Ba-Charvet and Chédotal, 2002), results consequently in their involvement in neurological 
diseases such as hereditary epilepsy and X-linked stationary night blindness (Bech-Hansen et al., 
2000; Kalachikov et al., 2002; Morante-Redolat et al., 2002; Pusch et al., 2000). Since Lingo-1 is a 
leucine rich repeat protein, and considering its genetic locus is in a chromosomic region associated 
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with a high risk for a number of psychiatric disorders, Lingo-1 makes for an ideal candidate for study 
in a vast array of neurological disorders. 
Within the healthy adult human brain Lingo-1 RNA expression was found to be abundantly and 
almost exclusively expressed in the central nervous system (Carim-Todd et al., 2003). A closer look at 
the distribution of Lingo-1 across the adult human brain showed that expression was highest in the 
cerebral cortex (Carim-Todd et al., 2003), a region heavily involved in sensory-motor function, 
cognition and working memory; the hippocampus (Carim-Todd et al., 2003), responsible for long 
term memory and the encoding and retrieval of multi-sensory information; the amygdala (Carim-Todd 
et al., 2003), a region highly implicated in the stress response (Stork and Pape, 2002), as well as the 
thalamus; with a more constant and basal level of expression across the remainder of the brain 
(Carim-Todd et al., 2003). In the context of neurological and psychiatric disorders, these brain regions 
that have been identified as highly expressing Lingo-1 transcripts, have also been heavily implicated 
in neuropsychological disorders such as stress and panic disorders (Stork and Pape, 2002), 
Parkinson’s Disease (Inoue et al., 2007) and Alzheimer’s Disease (Zhu et al., 2007), as well as 
schizophrenia (Fung et al., 2010), temporal lobe epilepsy (Goffin et al., 2011) and amnesia (Jarrard, 
2001), thus potentially implicating Lingo-1 in a wide variety of central nervous system disorders. 
To confirm the findings of a differential expression pattern of Lingo-1 across the adult human brain, 
and due to the high degree of identity (99.5%) between human and mouse orthologs of Lingo-1, levels 
of Lingo-1 mRNA have been examined in both the adult mouse brain (Carim-Todd et al., 2003), as 
well as across different stages of neurodevelopment from embryonic stages to adulthood in both the 
mouse (Carim-Todd et al., 2003) and the rat (Mi et al., 2004). Both mouse and rat results confirmed 
first of all that the expression of Lingo-1 is highly specific and is confined to the adult central nervous 
system. Similarly, the highest levels of expression were again found in the neocortex (Carim-Todd et 
al., 2003; Mi et al., 2004), hippocampus, thalamus and amygdala, in addition to the entorhinal cortex 
and various other components of the limbic system (Carim-Todd et al., 2003). While Lingo-1 is a 
highly expressed central nervous system transcript in the adult human, rat and mouse brain, it is 
ubiquitously expressed in the embryonic mouse up until embryonic day E7.5 (Carim-Todd et al., 
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2003). By E17.5 Lingo-1 is expressed exclusively within the central nervous system with the highest 
levels detectable within the neocortex, hippocampus, piriform cortex, and amygdala (Carim-Todd et 
al., 2003) corresponding to similar regions that presented with the highest expression levels in the 
adult mouse, rat and human, thus demonstrating that Lingo-1 is likely to have a highly conserved 
function throughout development across a variety of mammalian species. 
Neuronal sprouting and myelination are developmental milestones and are an integral part of 
neurodevelopment. Furthermore, Lingo-1 has been shown to be expressed early in embryonic 
development as described above. Accordingly in normal brain development, Lingo-1 is a potent 
negative regulator of myelination and neurite outgrowth, both of which are key neurodevelopmental 
processes. Lingo-1 was also reported to be expressed on oligodendrocytes where it plays an important 
role in the inhibition of oligodendrocyte differentiation and axon myelination (Mi et al., 2005). 
Myelination was shown to be inhibited by endogenous Lingo-1 and antagonism of Lingo-1 was able 
to reverse this inhibition (Mi et al., 2005). In support of these findings, electron microscope studies 
have shown increased numbers of myelinated axons within the spinal cord of Lingo-1 knockout mice 
compared to their wild type littermates (Mi et al., 2007, 2005). In contrast, transgenic mice 
overexpressing Lingo-1 show a delayed onset of myelination (X. Lee et al., 2007).  A study by Mi et 
al. not only showed that Lingo-1 interacts with both NgR and p75, as a part of the receptor complex, 
but also proved that it is capable of activating ras homolog gene family member A (RhoA), a small 
GTP-binding protein, and mediating the activity of myelin inhibitors. The Lingo-1 cytoplasmic 
domain was reported to be essential in providing the signal to activate RhoA, and thus to inhibit 
axonal outgrowth and myelination (Mi et al., 2004). Without the intracellular domain of Lingo-1, 
neurite outgrowth is restored in vitro, due to the interruption of the interaction between Lingo-1 and 
its co-receptor binding partners (Mi et al., 2004). 
3. Lingo-1 Signaling Pathways 
In addition to the NgR/p75 or TROY co-receptors, Lingo-1 is able to interact with additional co-
factors and/or co-receptors, leading to the activation of further downstream signaling pathways, 
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resulting in the regulation of neuronal survival, axon regeneration, oligodendrocyte differentiation, 
and myelination processes in the brain (Figure 1). 
3.1. NgR/p75 or TROY Complex 
NgR is encoded by the NgR gene (also known as RTN4R), located at locus 22q11.2 in humans, a 
chromosomic region that has been previously identified as being involved in many psychiatric 
disorders. A faulty NgR possibly caused by mutations within the gene itself, could result in abnormal 
axonal connections. This hypothesis has caused much interest among researchers due to the large 
number of neuropathologies that present with axonal abnormalities.  
Studies have also shown that NgR plays a role in synaptic plasticity (Budel, 2007; Josephson et al., 
2003; McGee and Strittmatter, 2003; Trifunovski et al., 2004), thus it has been considered that any 
aberrant enhancement of neuronal plasticity during neural development may be caused by a reduction 
or complete loss of NgR function during the last phases of development (Budel, 2007; Budel et al., 
2008). Alteration of activity-driven synaptic plasticity at Schaffer collateral-CA1 synapses; and 
abnormalities of dendritic spine shape have been previously observed in several animal studies, 
notably including the use of NgR null mice (Lee et al., 2008; Raiker et al., 2010), suggesting a key 
role of NgR in both of these processes. 
NgR is expressed primarily on the axons of a subpopulation of neurons, including cerebral cortical 
pyramidal neurons and cerebellar Purkinje cells (Kevin C Wang et al., 2002). In normal brain 
development, oligodendrocytes are responsible for regulating axonal growth via the Nogo protein and 
its receptor, NgR. Nogo binds to the leucine-rich repeat domains of NgR and facilitates the inhibition 
of axon growth (Hu and Strittmatter, 2004). NgR is a 473-residue protein, anchored to the neuronal 
membrane by a Glycosyl Phosphatydyl Inositol component. NgR protein is primarily comprised of a 
leucine-rich repeat ectodomain domain (similar to the one of Lingo-1), capped by N-terminal and C-
terminal cysteine rich molecules (He et al., 2003). 
To our knowledge, levels of NgR protein expression in post-mortem tissue have only ever been 
reported in the hippocampus in a cohort for Alzheimer’s Disease (Zhu et al., 2007). Interestingly, 
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NgR expression was increased in the hippocampus of patients suffering from Alzheimer’s Disease 
suggesting that NgR may play a common role in a larger scope of brain disorders. The levels of 
expression of the neurotrophin receptor p75, one of the direct binding partners involved in the 
downstream signaling of NgR with Lingo-1 or TROY, was also found to be higher in post-mortem 
brain tissue from Alzheimer’s Disease patients (Fujii and Kunugi, 2009), supporting the implication 
of the NgR/p75 pathway in this disorder. 
The Lingo-1 co-factor p75, is a well-defined member of the tumor necrosis factor receptor (TNFR) 
superfamily and was originally identified as a low-affinity neurotrophin receptor (Rabizadeh and 
Bredesen, 2003). The p75 gene is located at the human chromosomic region 17q21-22 and codes for a 
427 amino acid residue protein (Lotta et al., 2014). p75 has a well-established role in the nervous 
system, controlling the survival and differentiation of neurons (Dechant and Barde, 2002).  
While selective knockdown of p75 in mice results in severe ataxia making detailed behavioural 
testing near impossible (von Schack et al., 2001), it has been shown that interfering with the function 
of the p75 receptor suppresses neurotrophin activity and results in schizophrenia related 
endophenotypes (Rajakumar et al., 2004). p75 is a receptor for all mature and developing 
neurotrophins (Barker, 2004). Considering the implication of brain-derived neurotrophic factor 
(BDNF), the most widely studied neurotrophin and ligand for p75, with neurodegenerative and 
neuropsychiatric diseases such as Alzheimer’s disease, depression and schizophrenia, it is reasonable 
to consider that the neurotrophic receptor p75 itself, may play vital roles in the pathogenesis of a wide 
variety of neurological disorders (Fujii and Kunugi, 2009).  The loss of the p75 gene from neurons has 
been shown to render them incapable of activating RhoA, subsequently inhibiting neurite outgrowth 
in the presence of myelin inhibitors (Mi et al., 2004; Kevin C. Wang et al., 2002b), providing another 
plausible link to a neurodevelopmental role in psychiatric disorders. 
As part of the Lingo-1/NgR complex, the p75 neurotrophin receptor is specifically responsible for 
transmitting intracellular signals. Certain neurons lacking p75 show neither RhoA activation, nor do 
they exhibit neurite growth inhibition in the presence of myelin associated inhibitors, suggesting that 
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p75 plays a significant role in the transduction of inhibitory NgR signals in vitro (Kevin C Wang et 
al., 2002). On the other hand, some NgR containing cell types not expressing p75, have still been 
found to transduce inhibitory NgR signals (Kevin C. Wang et al., 2002a), leading to the discovery of 
TROY as a functional homolog of p75 within the signaling complex (Shao et al., 2005). 
TROY is a type I membrane protein belonging to the same tumor necrosis factor subfamily as p75, 
and is encoded by the TNFSF19 gene at human chromosome 13q12.11-12.3. Despite TROY 
belonging to the same family as p75, unlike p75, TROY is widely expressed in adult neurons where it 
can substitute for p75 in the Lingo-1/NgR/p75 signaling complex in the presence of myelin associated 
inhibitors in neurons lacking p75 (Park et al., 2005; Shao et al., 2005). TROY is abundantly expressed 
throughout neurodevelopment in neural stem cells located in the ventricular and subventricular zones, 
and is also found to be more abundantly present throughout the adult central nervous system than its 
homolog p75 (Hisaoka et al., 2003; Kojima et al., 2000; Park et al., 2005; Shao et al., 2005). TROY 
and Lingo-1 are expressed together in subpopulations of reactive astrocytes, macrophages/microglia 
and neurons, but not in oligodendrocytes (Satoh et al., 2007). Dominant-negative forms of p75 or 
TROY, in addition to both p75 and TROY knockout mice, have reduced levels of activated RhoA and 
enhanced neurite outgrowth in the presence of myelin inhibitors (Park et al., 2005; Shao et al., 2005; 
Kevin C. Wang et al., 2002b). 
Neurotropic growth factors are well known to regulate many aspects of neuronal development and 
function (Huang and Reichardt, 2001; Segal, 2003). Lingo-1 can also interact with the complex 
neurotrophin, nerve growth factor (NGF)/Trk receptor tyrosine kinase (RTK) TrkA, which leads to 
the regulation of the expression of genes involved in oligodendrocyte differentiation and myelination, 
such as oligodendrocyte transcription factor 2 (olig 2) and natural killer cell-associated antigen 2 
homeobox 2 (nkx2.2) (Zhou et al., 2001). 
The Lingo-1/NgR/p75 or TROY complex was the first cellular complex identified to determine the 
functions of Lingo-1 in the brain. The characterization of the serine threonine kinase With No Lysine 
K (WNK1) as both a modulator of the trimolecular receptor complex and as a direct downstream 
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signaling partner of Lingo-1 has highlighted the importance and expansive nature of Lingo-1 
functions in the brain. 
3.2. WNK1 
WNK1, a part of a distinct subfamily of serine threonine kinases implicated in the binding of ATP and 
catalyzing phosphoryl transfer (Hanks et al., 1988), is expressed abundantly in the brain (Choate et 
al., 2003; Xu et al., 2000). WNK1 has been shown to be co-localized with Lingo-1 in cortical cultured 
neurons (Zhang et al., 2009) in addition to being shown as a direct binding partner to Lingo-1 through 
co-immunoprecipitation experiments with both brain tissue and cell lysates (Zhang et al., 2009). 
Considering that little is known about the regulation and function of WNK1 in the central nervous 
system, there are an abundance of genetic studies regarding WNK1 gene (located on chromosome 
12p13.3) mutations. Interestingly, the disruption of the WNK1 gene in mice leads to death of the 
embryo at day 13 (Zambrowicz et al., 2003), suggesting an essential role of WNK1 in embryonic and 
neural development, which is a critical period implicated in a number of neurological and 
neuropsychiatric disorders. Furthermore, large intronic deletions in the WNK1 gene, leading to an 
increase in WNK1 mRNA, have been linked to an inheritable hypertension syndrome (Wilson et al., 
2003), in addition to genetic variations located in the regulatory 5’ region of the WNK1 gene also 
being associated with hypertension (Han et al., 2011). WNK1 gene expression has also been 
consistently reported to be upregulated in the prefrontal cortex of schizophrenia sufferers in genome 
wide association studies (Maycox et al., 2009; Mistry et al., 2012), suggesting a role in this disorder 
as well. 
The suppression of WNK1 expression by RNA interference has been shown to promote neurite 
extension and eliminate the inhibitory response to Nogo in cortical cultured neurons. In addition, the 
overexpression of WNK1 (123-510) reduces Nogo-induced inhibition of neurite extension rather than 
strengthening it, and inhibits the activation of RhoA (Zhang et al., 2009). The over expression of 
WNK1 (123-510) was also found to significantly reduce the interaction between endogenous WNK1 
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and Lingo-1, suggesting that this serine threonine kinase may serve as a binding platform for Lingo-1, 
however the kinase activity may not be necessary for Lingo-1 signaling (Zhang et al., 2009). 
3.3. Myt1 and Myt1l 
Myelin Transcription Factor 1 (Myt1) and its homologue Myelin Transcription Factor 1-like (Myt1l) 
are postmitotic neuronal specific zinc finger proteins expressed in the developing brain (Armstrong et 
al., 1995; Bellefroid et al., 1996). They are coded for by two independent genes Myt1 and Myt1l 
respectively on human chromosomes 20q13.33 and 2p25.3.  Myt1 expression appears to be present in 
both neural and glial lineages, however in the adult brain, Myt1 is not expressed on neurons 
(Armstrong et al., 1997). In contrast, Myt1l does not appear to be found in either the glial lineage, nor 
on glial cells in the adult brain, however its transcripts are most abundantly expressed in the prenatal 
brain during the development of neurons and in differentiating neurons suggesting that it plays an 
important role in neuronal differentiation (Kim et al., 1997). 
Myt1l has been reported to directly interact with the intracellular domain of Lingo-1, suggesting that 
Lingo-1 may regulate Myt1l transcription factor activity by affecting its subcellular localization 
(Llorens et al., 2008). It is thought that this may occur in two different ways: firstly Lingo-1 may 
interact with Myt1l to regulate its transcription factor activity by retaining it in the cytoplasm; or 
secondly, Lingo-1 may transduce intracellular signals by docking additional Myt1l cofactors or 
modifying enzymes (Llorens et al., 2008). Myt1 and Myt1l display a high degree of identity, and 
therefore are highly likely to share the same binding sites, considering the ability of the Myt1l protein 
to bind the oligonucleotide sequence containing the proteolipid protein site that was originally 
intended to clone Myt1. It has therefore been suggested that Lingo-1 may interact with Myt1 in 
oligodendrocytes the way that Lingo-1 interacts with Myt1l in neurons. Since it is known that Lingo-1 
expression in oligodendrocytes and neurons is necessary for preventing myelination, it seems 
reasonable to hypothesize that these effects are mediated by an interaction between Lingo-1 and Myt1 
and Lingo-1 and Myt1l in oligodendrocytes and neurons respectively (Llorens et al., 2008). Lingo-1 
and Myt1 gene expression have been found to be increased when adult nerve cells were exposed to 
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traumatic injuries and in demyelinated lesions in rodent and human central nervous system injuries 
respectively (Mi et al., 2004; Vana et al., 2007). 
3.4. EGFR/PI3-K/Akt Pathway 
The Epidermal Growth Factor Receptor (EGFR), also known as ErbB-1, triggers the activation of the 
Phosphoinositide 3-kinase (PI3-K)/Akt signaling pathway leading to DNA synthesis and cell 
proliferation including neuronal survival and growth (Brunet et al., 2001; Inoue et al., 2007; Oda et 
al., 2005). The binding of myelin inhibitors to NgR, has been shown to trigger phosphorylation of 
EGFR in a Ca2+ dependent manner (Koprivica et al., 2005), however EGFR activation by its own 
ligand, Epidermal Growth Factor (EGF), is not sufficient to inhibit axonal-outgrowth (Koprivica et 
al., 2005), thus it is reasonable to speculate that receptor transactivation of EGFR by the NgR 
complex may activate a different set of signaling cascades (Schwab et al., 2006). More recently 
studies have shown that some LRR Ig-containing proteins are able to influence growth factors by 
modulating pathways related to EGFR signaling (Goldoni et al., 2007; Gur et al., 2004), indicating 
that it may in fact be due to Lingo-1 signaling that NgR is able to affect EGFR. Lingo-1 has since 
been shown to directly bind to EGFR using the EGFR-like tyrosine phosphorylation site in its 
cytoplasmic domain to negatively regulate the EGFR/Akt signaling pathway, which has been notably 
implicated in the pathophysiology of schizophrenia (Huang and Chen, 2009; Inoue et al., 2007; Koros 
and Dorner-Ciossek, 2007). Through immunoprecipitation, cell culture and brain tissue experiments, 
endogenous Lingo-1 was found to reduce EGFR levels mediated by a direct physical interaction 
(Inoue et al., 2007). 
However the complete mechanisms underlying the inhibition of EGFR expression and function by 
Lingo-1 remain unclear. It has been suggested that this inhibition may be caused by Lingo-1 
accelerating the internalization and degradation of EGFR and so reducing the availability of EGFR on 
the neuronal membrane. Another potential mechanism suggests that Lingo-1 can directly inhibit the 
phosphorylation of EGFR and thus decrease PI3-K/Akt signaling pathway activity, resulting in 
decreased neuronal survival and growth (Inoue et al., 2007). The potential role of Lingo-1 as an 
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inhibitor of neuronal survival through the Akt signaling pathway enhances the hypothesis of a role of 
Lingo-1 signaling in the pathogenesis of a number of neuropsychiatric disorders. Considering the role 
of Lingo-1 in directly negatively regulating the EGFR/PI3-K/Akt signaling pathway, Lingo-1 has 
been investigated in relation to dopamine neuron survival, growth and function (Inoue et al., 2007). It 
was found that all of these factors were improved with Lingo-1 antagonism, and that inhibiting Lingo-
1 also increased EGFR and phospho-Akt levels in the absence of myelin inhibitors and promoted 
retinal cell survival (Fu et al., 2008; Inoue et al., 2007). 
Interestingly, downstream Lingo-1 signaling partners WNK1 and Myt1 have also been shown to be 
implicated in EGFR/PI3-K/Akt signaling. WNK1 has been identified as a substrate for Akt signaling, 
and the phosphorylation of WNK1 is inhibited by PI3-K inhibitors, thus suggesting that WNK1 is 
phosphorylated via the PI3-K/Akt signaling pathway (Jiang et al., 2005). Furthermore, Myt1 was 
reported to be inhibited and significantly downregulated by Akt phosphorylation (Okumura et al., 
2002). 
Since Lingo-1 signaling plays a pivotal role in repressing neurite outgrowth, oligodendrocyte 
differentiation and myelination and keeping in mind its expression at an early stage of development, 
the implication of Lingo-1 and its signaling pathways in a wide variety of neurological pathologies 
seems apparent. 
4. Role of Lingo-1 in Neurological Pathologies 
A wide range of central nervous system diseases including spinal cord injury, traumatic brain injury, 
multiple sclerosis, Parkinson’s disease and essential tremor, as well as Alzheimer’s disease, epilepsy 
and glaucoma; are neurodegenerative disorders resulting in neuronal death, axon degeneration, gliosis 
and demyelination. Lingo-1 and its signaling partners have been shown to be implicated in all of these 
disorders, due to their role in the inhibition of axonal outgrowth, neuronal death, oligodendrocyte 
differentiation and myelination (see Figure 1 and Supplementary Materials). Furthermore, a number 
of preclinical studies have shown that various methods of antagonizing Lingo-1 result in neuronal and 
oligodendroglial survival, axonal growth and remyelination. 
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4.1. Spinal Cord Injury, Traumatic Brain Injury and Multiple Sclerosis 
The vast majority of studies on Lingo-1 in neuropathological states are performed in relation to 
multiple sclerosis and traumatic injury to the central nervous system due to the inhibitory role of 
Lingo-1 in neurite outgrowth, oligodendrocyte differentiation and myelination, hindering the 
regeneration of the injured nervous system, whether from endogenous or exogenous processes. 
Spinal cord injury results in damage to the axonal tracts that are responsible for controlling motor and 
sensory function (Ji et al., 2006). Lingo-1 has been shown to be detected in the axonal tracts of 
adolescent rat spinal cords following injury (Mi et al., 2004). Further to this, a five-fold increase in 
Lingo-1 mRNA levels was detected at 14 days post injury (Mi et al., 2004). Lingo-1-Fc, a soluble 
form of Lingo-1, has also been shown to antagonize Lingo-1 signaling pathways by inhibiting the 
binding of Lingo-1 to NgR, resulting in vast improvements in the functional recovery of rats 
following lateral hemisection of the spinal cord. Additionally these rats displayed elevated levels of 
axonal sprouting and increased oligodendrocyte and neural survival due to Lingo-1-Fc blocking RhoA 
activation (Ji et al., 2006). Lingo-1-Fc treatment was also found to enhance plasticity in the injured 
spinal cord through the promotion of sprouting of collateral neurons; however whether Lingo-1-Fc is 
able to promote cortical plasticity remains to be determined (Ji et al., 2006). These data demonstrate a 
functional role of Lingo-1 in vivo and suggest that Lingo-1 may be a viable target for the treatment of 
spinal cord injury. 
Traumatic brain injury characteristically involves the necrotic and apoptotic death of cells in the brain 
in vulnerable areas such as the cerebral cortex and hippocampus (Conti et al., 1998; Raghupathi, 
2004; Royo et al., 2003), two areas known to highly express Lingo-1 in both the adult stage of life and 
throughout development (Carim-Todd et al., 2003; Mi et al., 2004). RhoA signaling is largely 
responsible for the neuronal response to neuronal inhibitory proteins and the regeneration (or lack 
thereof) of damaged axons (Dubreuil et al., 2006). Significant RhoA upregulation (Brabeck et al., 
2004) and activation has been reported  in both the cortex and hippocampus following traumatic brain 
injury (Dubreuil et al., 2006). The activation of Rho GTPases occurs during synaptic remodeling, 
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neuronal activity and synaptic plasticity in the central nervous system (Luo, 2002; O’Kane et al., 
2004, 2003). Since it is widely established that Lingo-1 mediates axonal outgrowth, oligodendrocyte 
differentiation and axon myelination largely due to its interaction with, and activation of RhoA, it has 
been hypothesized that Lingo-1 plays a significant inhibitory role in this debilitating neurological 
disorder. In support of this, the NgR inhibitor MAG has been shown to consistently improve a number 
of behavioural outcomes in rats using an experimental traumatic brain injury paradigm (Thompson et 
al., 2006). Furthermore, Lingo-1 antagonism using Lingo-1-Fc, has been shown to inhibit RhoA 
activation both in vitro in cultured cerebellar granule neurons (Mi et al., 2004), and in vivo in models 
of spinal cord injury (Ji et al., 2006). Since Lingo-1-Fc is able to block the interactions between 
Lingo-1 and NgR, it seems reasonable that blockade of RhoA activation occurred at the level of 
Lingo-1/NgR/p75 or TROY complex. 
In addition to its role as part of the NgR trimolecular receptor complex in neuronal processes, Lingo-1 
has also been shown to be expressed on oligodendrocytes where it able to negatively modulate 
oligodendrocyte differentiation and axon myelination (Mi et al., 2005). Lingo-1-Fc was found to have 
a neuroprotective effect on the survival of both neurons and oligodendrocytes after spinal cord injury 
in rats (Ji et al., 2006). Furthermore antagonizing endogenous Lingo-1 either by Lingo-1 RNA 
interference, dominant-negative Lingo-1, an anti-Lingo-1 antibody, or soluble Lingo-1; resulted in 
more highly differentiated and mature oligodendrocytes (with more branching and increases in the 
lengths of processes), in addition to the formation of abundant myelin sheaths (Mi et al., 2005). As a 
result of these experiments, Lingo-1 antagonists were examined as a potential candidate in the 
treatment for multiple sclerosis. Although the underlying molecular mechanisms constituting the 
presentation of multiple sclerosis remain unknown, the degree of inflammatory demyelination in this 
debilitating disorder correlates significantly with the extent of axonal damage that begins in the early 
stages of multiple sclerosis (Lassmann, 2003). 
Lingo-1 protein expression has been shown to be decreased in both the prefrontal cortex and 
cerebellar cortex of multiple sclerosis brains, while expression of its co-receptor TROY was found to 
be significantly  increased in the same brain regions compared to samples from subjects without 
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multiple sclerosis (Satoh et al., 2007). However due to the very limited sample size used in this study, 
the results have to be considered with caution. In contrast to this result, the immunoreactivity of both 
Lingo-1 and TROY were found to be enhanced in subpopulations of astrocytes and 
macrophages/microglia from the prefrontal and parietal cerebral cortex in multiple sclerosis brains 
(Satoh et al., 2007). Additionally, levels of NgR are up-regulated in reactive astrocytes and 
macrophages/microglia in chronic active demyelinating lesions of multiple sclerosis (Satoh et al., 
2005), suggesting the implication of the Lingo-1/NgR/TROY signaling complex in the glial-neuronal 
and glial-glial interactions underlying multiple sclerosis. Considering these significant interactions, 
Garcia-Martin et. al. (García-Martín et al., 2013) set out to investigate two Lingo-1 variants 
(rs9652490 and rs11856808), previously associated with other neurological pathologies including 
essential tremor (Stefansson et al., 2009; Vilariño-Güell et al., 2010a) and Parkinson’s disease 
(Vilariño-Güell et al., 2010a, 2010b). Despite no significant associations being found between these 
genetic variants and multiple sclerosis in a Caucasian Spanish population (García-Martín et al., 2013), 
evidence continues to stack up further implicating Lingo-1 in the pathogenesis of multiple sclerosis. 
This is further illustrated by animal studies. Myelination of central nervous system axons in Lingo-1 
knockout mice was found to present earlier in life compared to their wild-type littermates (Mi et al., 
2007). In addition these mice have a greater resistance to the development of MOG-induced 
experimental autoimmune encephalomyelitis (EAE) (Mi et al., 2007), a model commonly used to 
model human demyelinating diseases including multiple sclerosis. Furthermore, treatment with 
Lingo-1 antagonizing antibodies and by RNA interference, leads to functional recovery and increases 
the axonal integrity of mice with (EAE) (Mi et al., 2007; Wang et al., 2014). Lingo-1 antagonism has 
been shown to induce both oligodendrocyte differentiation and remyelination using three different 
demyelination animal models; the EAE model, and pharmacological toxin-induced models of 
demyelination: lysophosphatidylcholine-(LPC) and cuprizone (Mi et al., 2009). 
The promising results of antagonizing Lingo-1 to treat demyelination has led to the development of 
BIIB033 (also known as Li81); the first fully human, IgG1 monoclonal Lingo-1 antibody to enter 
clinical development (Mi et al., 2013). BIIB033 has been specially engineered to have reduced Fc 
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gamma and complement effector functions compared with wild type IgG, and binds human Lingo-1 
with high affinity and specificity (Mi et al., 2013). Stage I clinical trials have demonstrated that 
BIIB033 is safe for use in humans, both in healthy controls, and multiple sclerosis patients, and has 
been found to be well tolerated, up to 100 mg/kg, and is able to cross the blood brain barrier resulting 
in cerebral spinal fluid levels of greater than 90% effective concentration when given at intravenous 
doses of greater than 10 mg/kg (Tran et al., 2012, 2014). Further to this, structural studies examining 
how BIIB033 binds to Lingo-1 have shown that its binding to the convex surface of the leucine-rich 
repeat domain of Lingo-1 within repeats 4-8, blocks the Lingo-1-Lingo-1 contact points and prevents 
oligomerization of the protein (Pepinsky et al., 2014). This indicates that BIIB033 interferes with the 
ability of Lingo-1 to form homotetramers, with the rearrangement of the quaternary structure of 
Lingo-1 providing a model for how the antibody inhibits Lingo-1 function in oligodendrocytes 
(Pepinsky et al., 2014). Phase II clinical trials for BIIB033 are currently underway, and will provide 
vital information on the impact of targeting Lingo-1 as a treatment for multiple sclerosis (Brugarolas 
and Popko, 2014). 
4.2. Parkinson’s Disease and Essential Tremor 
Parkinson’s disease and essential tremor are age-related movement disorders which have a prevalence 
of approximately 1-2% and 3-6% of individuals over the age of 65 respectively (de Rijk et al., 2000; 
Louis et al., 2009). While the clinical presentation of Parkinson’s disease and essential tremor do 
overlap, essential tremor patients typically present with tremor on action, or postural tremor, whereas 
Parkinson’s symptoms are typically more severe in that they present as tremor at rest, usually 
asymmetrical, in addition to experiencing bradykinseia, rigidity and postural instability (Fekete and 
Jankovic, 2011; Shahed and Jankovic, 2007). 
Lingo-1 was first implicated in Parkinson’s disease, when it was discovered that levels of Lingo-1 are 
upregulated in the substantia nigra of post mortem Parkinson’s disease brains compared to matched 
controls and in neurotoxic animal models of Parkinson’s disease (Inoue et al., 2007). Lingo-1 
antagonism by a variety of pharmacological and genetic mechanisms produces neuroprotective effects 
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on dopaminergic neurons in the midbrain (Inoue et al., 2007). Dopamine neuron survival and a 
significant reduction in behavioural abnormalities were observed in Lingo-1 knockout mice compared 
to wild-types (Inoue et al., 2007). Similar effects were also observed in wild-type mice in vivo, and in 
vitro in cultured dopaminergic neurons treated with Lingo-1 antagonists (Inoue et al., 2007). The 
treatment of dopaminergic neurons with a dominant-negative form of Lingo-1, an anti-Lingo-1 
antibody, and Lingo-1-Fc resulted in a significant improvement in neuronal survival during a 
mitochondrial toxicity paradigm used to model Parkinson’s disease in vitro (Inoue et al., 2007). 
Interestingly, the neuroprotection observed in  in vivo and in vitro studies, was accompanied by an 
activation of the EGFR/PI3-K/Akt signaling pathway which is also implicated in the pathology of 
Parkinson’s disease (Brunet et al., 2001; Farkas and Krieglstein, 2002; Iwakura et al., 2005; Onyango 
et al., 2005; Timmons et al., 2009). As mentioned above in section 3.4, Lingo-1 is able to directly 
bind to EGFR (Inoue et al., 2007), therefore the pharmacological inhibition of Lingo-1 by the Lingo-1 
antagonists, suppresses its binding to EGFR resulting in activation of the EGFR/PI3-K/Akt signaling 
in the in vitro and in vivo models of Parkinson’s disease (Inoue et al., 2007). 
Expression of Lingo-1 protein has been found to be significantly increased in the cerebellum 
(particularly at the basket cell pinceau along the purkinje cell axon initial segment), but not in the 
occipital cortex of essential tremor patients (Kuo et al., 2013). The highly enriched pinceau processes 
labeled with Lingo-1 were not only more commonly observed in the cerebellum of essential tremor 
patients compared to controls, but were also significantly more elongated in the cerebellum of 
essential tremor patients compared to those seen in both cerebellar degenerative disorder patients and 
controls (Kuo et al., 2013). This suggests that Lingo-1 pinceau are a common feature of both essential 
tremor and cerebellar degenerative disorder, however the longer pinceau processes are specific to the 
essential tremor pathology, providing a novel pathological link between Lingo-1 and essential tremor. 
While environmental factors are proposed to play a role in the onset of both Parkinson’s disease and 
essential tremor, a number of genetic factors have been recognized to contribute to both disorders 
(Deng et al., 2007; Spanaki and Plaitakis, 2009). There is an abundance of genetic evidence 
implicating Lingo-1 with both Parkinson’s disease and essential tremor (Vilariño-Güell et al., 2010a, 
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2010b), with an equal number of studies claiming no implication of Lingo-1 genetic variations with 
these disorders (Białecka et al., 2010; Wu et al., 2011). As a result, in 2012 meta-analyses were 
conducted on the results of genetic studies for both Parkinson’s disease and essential tremor and it 
was confirmed that the Lingo-1 single nucleotide polymorphisms (SNPs) rs9652490 and rs11856808 
of which both had been claimed to be both associated and not associated with essential tremor, were 
in fact associated with the disorder (Jiménez-Jiménez et al., 2012). In the case of Parkinson’s disease 
the rs9652490 SNP was found not to have an association with Parkinson’s disease following the meta-
analysis (Wu et al., 2012). 
4.3. Alzheimer’s Disease 
Alzheimer’s disease is the most prevalent cause of dementia in humans and is typically characterized 
by the early loss of neocortical synapses, the formation of neurofibrillary tangles and the 
accumulation of neuritic plaques within the hippocampus and temporal cortical regions of the brain 
(Khachaturian, 1985). One of the most hypothesized causes of the memory decline in the aging brain 
is the failure of synaptic plasticity with age (Foster, 1999). Lingo-1/NgR/p75 or TROY signaling was 
examined in the hippocampus and cerebral cortex from rats in an aging brain study (Trifunovski et al., 
2006). While there were no significant alterations observed in the mRNA expression of any of the 
receptor components or in the expression of the ligands OMgp or MAG; Nogo mRNA was found to be 
significantly reduced in hippocampal subregions, specifically the CA1, CA3, CA4 and dentate gyrus, 
with age. Additionally, a downregulation of NgR mRNA expression was supposedly caused by 
activity induced alterations in brain activity, which is required to induce plastic changes within the 
brain (Josephson et al., 2003). In addition, a simultaneous increase in both NgR and its ligand Nogo 
were hypothesized to be required to induce a locked conformational state in hippocampal and cortical 
microcircuitry in order to maintain the plastic changes (Josephson et al., 2003). Thus the decrease in 
Nogo mRNA expression in the hippocampus of aged animals may be related to the age-dependent 
decline of brain plasticity. 
 
21 
 
In contrast to these animal studies, Zhu et. al. have reported the expression of NgR to be increased in 
the hippocampus of Alzheimer’s disease patients (Zhu et al., 2007). While there was not an overall 
significant difference in the number of immunopositive NgR neurons in Alzheimer’s disease 
compared to control patients, there was a significant increase in the ratio observed between NgR 
immunopositive neurons to the total number of neurons within the hippocampus of Alzheimer’s 
patients compared to that of the control group. Additionally, NgR was found to be co-localized with 
the hyperphosphorylated tau protein, which is largely responsible for the formation of neurofibrillary 
tangles, in hippocampal cells of Alzheimer’s disease patients compared to controls. 
The hypothesis of dysfunctional Lingo-1 signaling in Alzheimer’s disease is also supported by a 
report of enriched Lingo-1 expression within the limbic system (Carim-Todd et al., 2003), a region 
largely affected in Alzheimer’s disease (Thiebaut de Schotten et al., 2014). In addition, NgR was 
found to be involved in the formation and deposition of amyloid-β peptide (Park et al., 2006), the 
main component in plaque formations (Hu et al., 2002). Due to is role in neuronal apoptosis and cell 
death, and more recent implication in the formation of neurofibrillary tangles, p75 also has a proposed 
role in the pathogenesis of Alzheimer’s disease (Hu et al., 2002). Similarly, Lingo-1 has been shown 
to directly bind to amyloid precursor protein, the precursor for amyloid-β peptide, and to modulate its 
processing by increasing the production of amyloid-β peptide from amyloid precursor protein when it 
is overexpressed (Bai et al., 2008); however this was not found to be modulated by the leucine-rich 
repeats of Lingo-1 (Stein and Walmsley, 2012). Additionally, Lingo-1 is able to regulate amyloid 
precursor protein proteolysis by interacting with amyloid precursor protein in the endosome/lysosome 
pathway where Lingo-1 can control and regulate the amount of amyloid precursor protein available 
for processing (de Laat, 2012). All of the above evidence supports the hypotheses that Lingo-
1/NgR/p75 signaling is implicated in the pathophysiology of Alzheimer’s disease. 
Furthermore, pharmacological blockade of EGFR antagonizes the formation of amyloid-β oligomers 
induced by EGFR activation, and improves memory impairment in animal models of Alzheimer’s 
disease, suggesting that EGFR would be an ideal target for Alzheimer’s disease therapy (Wang et al., 
2012). Since Lingo-1 can directly activate EGFR and due to its role in neuronal survival, we can 
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hypothesis that Lingo-1 may also be involved in the pathophysiology of Alzheimer’s disease through 
its interaction with EGF and EGFR. 
4.4. Tuberous Sclerosis, Focal Cortical Dysplasia and Temporal Lobe Epilepsy 
Tuberous sclerosis, focal cortical dysplasia and temporal lobe epilepsy are all very different types of 
neurological disorders; however they all have a common symptom: seizures. The expression of 
components of the Nogo-A signaling system have been investigated in samples taken from pediatric 
patients with tuberous sclerosis and focal cortical dysplasia type IIb, who were undergoing surgical 
procedures for the treatment of epilepsy. Both of these disorders are characterized by malformations 
of the cortex during development and as mentioned above, are both frequently associated with 
seizures (Yu et al., 2012). Both protein and mRNA levels for Nogo-A, NgR, Lingo-1, TROY and 
RhoA but not p75 were found to be upregulated in the cortex of patients from both tuberous sclerosis 
and cortical dysplasia compared to controls. Interestingly Nogo-A, NgR, Lingo-1 and TROY were all 
highly expressed in misshapen cells including dysmorphic neurons, balloon cells and giant cells (Yu 
et al., 2012). Lingo-1 and TROY were also identified in reactive astrocytes of the patient samples 
compared to controls. Together this research suggests that Nogo-A along with its signaling complex 
Lingo-1/NgR/TROY, but not Lingo-1/NgR/p75 may contribute to the development and/or progression 
of seizure activity in malformations of cortical development. 
In addition the Lingo-1/NgR/TROY signaling complex was found to be altered in an animal model of 
temporal lobe epilepsy; the BALB/cByJ-Kv1.1mceph/mceph (also known as mceph/mceph) mouse 
(Lavebratt et al., 2006). Temporal lobe epilepsy is the most common type of adult focal epilepsy that 
presents with progressive complex partial seizures with pathological brain overgrowth, or 
megalencephaly. Temporal lobe epilepsy principally affects the hippocampus and ventral cortex. 
Megalencephaly is a developmental disorder affecting around 2% of children worldwide and is 
largely thought to be caused by genetic abnormalities in the PI3-K/Akt signaling pathway which is 
known to be activated by Lingo-1 signaling. NgR mRNA expression was found to be significantly 
increased in the dentate gyrus in mceph/mceph mice compared to wild-types, with no other brain 
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regions displaying significant genotypic alterations in NgR expression. The NgR expression was 
however specifically restricted to neurons and predominantly observed in regions associated with high 
plasticity such as the cortex and hippocampus, both of which were also significantly enlarged in 
mceph/mceph mice compared to wild-types (Lavebratt et al., 2006). Additionally, Lingo-1 showed 
expression patterns throughout the brain similar to that of NgR, however a significant increase in 
Lingo-1 was observed in the CA3 region of the hippocampus, in addition to in the dentate gyrus 
ventral cortex and amygdala in the mceph/mceph mice compared to wild-types (Lavebratt et al., 
2006). The third member of the tripartite receptor complex TROY was the only component in the 
complex to be significantly downregulated in the brains of mceph/mceph mice; with the most 
prominent decrease being evident in the cortex and dentate gyrus, with slightly smaller reductions 
being evident in the CA1 region of the hippocampus and ventral cortex. Again these were all brain 
regions that were significantly enlarged in mceph/mceph mice compared to wild-types. Importantly, 
all of the dysregulations in the expression of NgR, Lingo-1 and TROY mRNA in the mceph/mceph 
mice were normalized when the mice were treated with carbamazepine, a commonly used 
anticonvulsant drug used for the treatment of epilepsy, with Lingo-1 dropping to levels even below 
that of wild-type mice following treatment (Lavebratt et al., 2006). Additionally, the cortical 
overgrowth in brain regions that were enlarged due to the genetic abnormality in the mceph/mceph 
mice was prevented by the treatment with carbamazepine. Furthermore, an alteration of the 
EGF/mTOR (mammalian target of rapamycin) signaling pathway has also been reported in the 
pathophysiology of epilepsy (Cho, 2011).  Due to the direct inhibitory effects of the EGF/EGFR 
signaling pathways, the implication of Lingo-1 through the EGF-mTOR pathway also seems 
appropriate in the context of epilepsy. 
Altogether, these results suggest that the Lingo-1/NgR/TROY and EGF/EGFR signaling pathways are 
involved in temporal lobe epilepsy, and that treatment with carbamazepine may be an effective 
treatment not only for seizures, but also for megalencephaly. 
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4.5. Glaucoma 
Since the optic nerve is still considered to be a part of the central nervous system, the role of Lingo-1 
in optic nerve disorders has been investigated. Glaucoma is a neurodegenerative disease characterized 
by abnormally high intraocular pressure and is the leading cause of blindness due to retinal ganglion 
cell death. Both Lingo-1 and NgR were found to be significantly upregulated in retinal ganglion cells 
following the use of an ocular hypertension paradigm in rats (Fu et al., 2011, 2008). Antagonizing the 
function of Lingo-1, either using Lingo-1-Fc or an anti-Lingo-1 antibody, or antagonizing NgR using 
soluble NgR (sNgR-Fc) has been shown to not only reduce the number of retinal ganglion cells that 
were lost after ocular hypertension, but also promote the survival of retinal ganglion cells following 
optic nerve transection (Fu et al., 2011, 2008). Lingo-1-Fc treatment was also shown to block RhoA 
signaling and promote Akt activation (Fu et al., 2008), thus the mechanism underlying Lingo-1 
antagonist induced neuroprotection is evidently mediated through the RhoA and PI3-K/Akt signaling 
pathways. Conversely, another two studies have shown that Lingo-1 may exert its neuroprotective 
effects on retinal ganglion cells following ocular hypertension by its interaction with BDNF/TrkB 
(tropomyosin receptor kinase B). Lingo-1 and BDNF were found to be co-expressed in retinal 
ganglion cells (Fu et al., 2009). Additionally Lingo-1 is able to form a complex with TrkB following 
ocular hypertension injury (Fu et al., 2010). Furthermore it was demonstrated that Lingo-1 antagonists 
(Lingo-1-Fc and an anti-Lingo-1 antibody) caused an upregulation of phospho-TrkB phosphorylation, 
leading to the survival of retinal ganglion cells (Fu et al., 2010). However a combined treatment of 
BDNF and Lingo-1-Fc resulted in activation of more TrkB than a treatment of BDNF alone (Fu et al., 
2009). Since the neuroprotective effects could be inhibited by an anti-BDNF antibody, this indicates 
that the regulation of the BDNF/TrkB signaling pathway by Lingo-1 is responsible for mediating the 
survival of the retinal ganglion cells. 
Most recently, myocilin has been identified as being involved in the Lingo-1/NgR mediated 
oligodendrocyte differentiation and myelination of the optic nerve (Kwon et al., 2014). Myocilin is a 
glycoprotein secreted by optic nerve astrocytes, and mutations in its gene MYOC, were the first 
genetic implications known to cause glaucoma, more specifically open-angle glaucoma (Stone et al., 
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1997). In both in vivo and in vitro studies, myocilin was found to mediate oligodendrocyte 
differentiation through direct interaction with both Lingo-1 and NgR (Kwon et al., 2014). 
Furthermore myocilin is involved in the myelination of the optic nerve in mice, and the differentiation 
of optic nerve oligodendrocytes is significantly delayed in Myocilin knockout mice, leading to 
decreased thickness of the myelin sheaths on the optic nerves of these mice compared to wild types. 
Overall these novel results have shown that myocilin plays a role in oligodendrocyte differentiation 
and myelination through its interactions with the Lingo-1/NgR complex. 
5. Lingo-1 Signaling: A New Role in Psychiatric Disorders  
Dysfunction of axonal growth and myelination has been prominently implicated by gene expression, 
histopathology and imaging studies, in a wide range of neuropsychiatric disorders including 
depression (Alexopoulos et al., 2002; Aston et al., 2005; Bae et al., 2006; Hannestad et al., 2006), 
obsessive compulsive disorder (Cannistraro et al., 2007; Jayarajan et al., 2012; Szeszko et al., 2005), 
post-traumatic stress disorder (Abe et al., 2006; Kim et al., 2005, 2006), bipolar disorder (Adler et al., 
2006, 2004), autism (Keller et al., 2007; Lange et al., 2010; J. E. Lee et al., 2007), and attention 
deficit hyperactivity disorder (Castellanos et al., 2003; Filipek et al., 1997; Rüsch et al., 2007; 
Semrud-Clikeman et al., 2000). However the vast majority of studies have shown an implication of 
axonal growth and myelination dysfunction in schizophrenia (Barley et al., 2009; Bartzokis et al., 
2003; Hakak et al., 2001; Schmitt et al., 2004; Shenton et al., 2001; Tkachev et al., 2003; Uranova et 
al., 2001; Walterfang et al., 2011, 2006). 
Until recently, no studies had ever specifically investigated a link between Lingo-1 in schizophrenia. 
We have provided the first evidence of an implication of Lingo-1 in schizophrenia, by observing 
alterations in the expression profiles of Lingo-1 and its signaling partner proteins in the dorsolateral 
prefrontal cortex (DLPFC) and hippocampus (CA1 and CA3) from post-mortem schizophrenia brains 
(Fernandez-Enright et al., 2014); regions highly relevant to the schizophrenia pathophysiology 
providing highly sought after, novel directions for therapeutic strategies. 
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Although Lingo-1 itself had never been implicated in schizophrenia, a number of nicotinic receptor 
genes and the myelination gene Lipidosin, located within the vicinity of the Lingo-1 locus at 
chromosomic region 15q24, had previously been shown to be associated with schizophrenia, along 
with several other myelination genes which were also reported to be downregulated in the prefrontal 
cortex in this disorder (Hakak et al., 2001; Tiwari et al., 2005; Tkachev et al., 2003; Weidenhofer et 
al., 2006). With Lingo-1 being a known myelination inhibitor and a negative modulator of 
oligodendrocyte differentiation when overexpressed (Mi et al., 2005), the investigation of  the role of 
Lingo-1 in schizophrenia seemed timely and topical. 
Previous studies have described significant reductions in prefrontal lobe white matter volume in 
patients with schizophrenia (Breier et al., 1992; Buchanan et al., 1998). However, a decrease in white 
matter anisotropy was consistently reported in schizophrenia patients, irrespective of their white 
matter volume (Buchsbaum et al., 1998; Lim et al., 1999; Tang et al., 2007). Thus, schizophrenia 
patients could present with compromised neuronal connectivity and/or directional coherence of white 
matter fibers (Lim et al., 1999), possibly due to the reported upregulation of Lingo-1 in schizophrenia 
(Fernandez-Enright et al., 2014). 
In support of the possible role of Lingo-1 in myelin dysfunction in schizophrenia, Lingo-1 knockout 
mice have been shown to have a higher and more differentiated percentage of mature 
oligodendrocytes than wild types (Mi et al., 2007, 2005). The typical onset of myelination in wild 
type mice occurs at PN5, however Lingo-1 knockout mice had already developed myelinated fibers at 
PN1. Additionally, no obvious changes were observed in the peripheral nervous system sciatic nerve, 
suggesting that myelination effects were limited to the central nervous system (Mi et al., 2005). 
As described above in section 4, Lingo-1 has been repeatedly implicated in a wide variety of central 
nervous system disorders resulting in emotional and mental disturbances, loss of motor skills and 
cognitive deficits; however in addition to its novel implication in schizophrenia (Fernandez-Enright et 
al., 2014), there is also evidence implicating the Lingo-1 chromosomic region 15q24 in a range of 
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neuropsychiatric disorders including autism spectrum disorder, and anxiety disorders such as panic 
and phobic disorders. 
To date, 15q24 deletion syndrome has been examined in a number of autism spectrum disorder 
cohorts, and from these studies, 15q24 deletion syndrome has been identified in approximately 0.1-
0.2% of individuals with autism spectrum disorders (Marshall et al., 2008; McInnes et al., 2010). 
However to our knowledge, of the individuals identified as having 15q24 deletion syndrome to date, 
21% of subjects present with autism spectrum disorder (Marshall et al., 2008; McInnes et al., 2010), 
and another 7% present with autistic features (McInnes et al., 2010; Sharp et al., 2007). Despite these 
implications, the true frequency of autism spectrum disorders in patients with 15q24 deletion 
syndrome is currently not known, as not all 15q24 deletion syndrome patients have been assessed for 
autism.  
Further to this, mild mental retardation and/or developmental delay is present in all patients identified 
as having microduplications in the 15q24 chromosomic region (El-Hattab et al., 2010, 2009; Kiholm 
Lund et al., 2008), in addition to one patient also testing positive for both Asperger’s syndrome, and 
attention deficit hyperactivity disorder (El-Hattab et al., 2009). Moreover interstitial duplications in 
15q24-26, engulfing Lingo-1 in its entirety, have been significantly associated with panic, 
agoraphobia and social phobia in families, and with panic disorder in non-familial cases, with 90% of 
patients fitting the diagnosis of one or more of the anxiety disorders having the chromosomic 
duplication (Gratacòs et al., 2001). Despite a number of groups trying to reproduce this finding, none 
have successfully done so (Henrichsen et al., 2004; Tabiner et al., 2003; Weiland et al., 2003; Zhu et 
al., 2004), therefore the finding by Gratacòs et. al. must be considered with caution. 
While Lingo-1 and its co-receptor NgR are highly involved in neurodevelopmental processes such as 
axonal outgrowth, they also play important roles in the mature brain. Both of these proteins have been 
previously reported to regulate experience-dependent synaptic plasticity (Josephson et al., 2003; 
McGee et al., 2005; Trifunovski et al., 2004), one of the important foundations in the development of 
learning and memory which has been shown to be dysfunctional in schizophrenia. 
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The results of our novel study, in concert with the current literature, suggest that downregulation of 
NgR and concurrent upregulation of Lingo-1 may be activity dependent characteristics of synaptic 
plasticity in schizophrenia. There is an abundance of evidence now supporting the concept that 
alterations in activity dependent plasticity (Shatz, 2009; Stephan et al., 2006), and changes in the 
restriction of myelin based plasticity genes in the postnatal brain, may be the underlying factor for the 
many cognitive and behavioural deficits reported in schizophrenia (C. J. Carter, 2006; C. S. Carter, 
2006; Davis et al., 2003; Davis and Haroutunian, 2003; Hakak et al., 2001). It has previously been 
considered that aberrant enhancement of neuronal plasticity during neural development in 
schizophrenia may be caused by a reduction or complete loss of NgR function (Budel, 2007; Budel et 
al., 2008); this is supported by our study demonstrating a downregulation of NgR in schizophrenia 
subjects (Fernandez-Enright et al., 2014). Furthermore, this is also supported by the presence of 
genetic variations in the NgR gene in 1-2% of the schizophrenia population (Budel, 2007; Budel et al., 
2008; Karayiorgou et al., 1995; Sinibaldi et al., 2004). Deletion of the chromosomic region 22q11, has 
an association with a risk of schizophrenia 25 times greater than the general population, making the 
22q11 deletion one of the strongest known genetic risk factors for schizophrenia (Bassett et al., 2003; 
Bassett and Chow, 1999). Further to this, children and adolescents with the 22q11 deletion have been 
found to have a high incidence of anxiety, depression, social withdrawal, attention deficit 
hyperactivity disorder, bipolar disorder, obsessive-compulsive behaviors and occasionally autism 
(Carlson et al., 1997; Kozma, 1998; Papolos et al., 1996; Woodin et al., 2001). Moreover, a 
spontaneous 3 Mb deletion at 22q11 has been found in 5.3% of patients in the largest cohort of very-
early onset childhood onset schizophrenia subjects to date (Sporn et al., 2004). Additionally, SNPs 
with functional roles and/or those resulting in a change in amino-acids (R377W, R227C, R399W, 
rs74315508, rs74315509 and L18L) within the NgR gene have been previously identified in 
schizophrenia subjects (Budel et al., 2008; Sinibaldi et al., 2004). Interestingly, two non-synonymous 
changes (rs74315508 and rs74315509) were found in patients who displayed predominantly negative 
symptoms which were strongly resistant to conventional and novel drug treatments (Sinibaldi et al., 
2004). 
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It has been well documented that memory impairment exists in schizophrenia (Aleman et al., 1999; 
Barch et al., 2001; Callicott et al., 2000; Weinberger et al., 1986). If impaired working memory is a 
hallmark of schizophrenia, then a downregulation of NgR, and NgR gene mutations known to be 
present in the schizophrenia population (Budel, 2007; Budel et al., 2008), could be considered 
possible grounds for the development of this memory dysfunction taking into consideration the role of 
NgR in regulating synaptic plasticity. In support of this hypothesis, NgR deficient mice have been 
shown to exhibit impaired working memory, despite their spatial memory acquisition remaining intact 
(Franowicz et al., 2002). NgR is the only established myelin associated inhibitor to display a memory 
phenotype (Akbik et al., 2012); however since NgR knockout mice have also been shown to display 
multiple schizophrenia related endophenotypes, a stronger link has been made between NgR 
downregulation or loss, and schizophrenia (Budel, 2007). Additionally NgR knockout mice are now 
considered to be an animal model for schizophrenia (Budel et al., 2008; Kim et al., 2004). 
Either the p75 neurotrophin receptor or its functional homolog TROY make up the remainder of the 
Lingo-1/NgR signaling complex, however despite the overwhelming evidence implicating NgR in 
schizophrenia, only a few studies have reported levels of expression of p75 in the post-mortem 
schizophrenia brain, where no change was reported in the hippocampus of schizophrenia subjects 
compared to controls in the Stanley consortium brains, however a decrease in p75 binding was seen in 
bipolar disorder subjects compared to controls in the same study (Dunham et al., 2009). Meanwhile, 
alterations in p75 signaling proteins have been found in the post-mortem fusiform gyrus from autism 
patients compared to controls; PI3-K and Akt were found to be significantly downregulated, and a 
trend towards an upregulation of the p75 neurotrophin receptor was also found (Fahnestock and 
Nicolini, 2014). Similar alterations were observed in the lateral temporal neocortex of rats using the 
valproic-acid induced rat model of autism (Fahnestock and Nicolini, 2014). Selective knockout of the 
p75 neurotrophin receptor from the cerebellar Purkinje cells of mice, results in autism-like behaviors 
including diminished social interaction, a lack of interest in novel environments, in addition to a 
decrease in the complexity of the dendritic arborization of their cerebellar Purkinje cells (Lotta et al., 
2014). When it comes to anxiety related disorders, there is conflicting information regarding p75. On 
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one hand p75 knockout mice have been shown to display increased anxiety behavior and difficulties 
recovering from stress compared to wild-types, with altered cholinergic transmission both at baseline 
and in response to acute stress (Martinowich et al., 2012). On the other hand, there is evidence to 
show that p75 knockout mice show markedly reduced anxiety levels, despite having increased fear 
memory compared to wild-type controls (Olsen et al., 2013). Furthermore, p75 knockout mice were 
found not to have altered anxiety-like behavior compared to wild-types in the elevated-plus maze, 
light-dark, hole-board, T-maze or forced swim tests, however in a test for despair and depression-like 
behaviors the knockout mice displayed increased mobility in the tail-suspension test compared to the 
wild-type controls (Catts et al., 2008). Considering that p75 is more highly expressed in the 
developing brain compared to the adult brain, where its expression is limited to certain neuronal 
subpopulations (Shao et al., 2005), examination of TROY in the central nervous system in relation to 
schizophrenia and other psychiatric disorders is warranted. Since TROY is a major partner of the 
Lingo-1/NgR/TROY complex, and considering the significant upregulation reported in the CA1, with 
no change in the CA3 of schizophrenia patients (Fernandez-Enright et al., 2014), additional 
mechanisms may be involved in the regulation of this protein which will need to be further 
investigated. Furthermore, a significant downregulation of TROY gene expression was found in the 
fibroblasts of major depressive disorder patients compared to matched healthy controls (Garbett et al., 
2014), further implicating the Lingo-1/NgR/TROY complex in a wider variety of neuropsychiatric 
disorders. 
Previous studies have shown that WNK1 is a negative regulator of cell growth via phosphorylation of 
the PI3-K/Akt signaling pathway (Jiang et al., 2005), and its overexpression was shown to be a 
negative regulator of Nogo-induced inhibition of neurite extension and RhoA (Zhang et al., 2009). 
WNK1 protein expression was found to be elevated in schizophrenia compared to control brains 
within the CA1, but not CA3 or DLPFC in schizophrenia compared to controls (Fernandez-Enright et 
al., 2014). This result was supported by previous literature reporting a consistent upregulation of 
WNK1 gene expression in DLPFC post-mortem tissue from schizophrenia sufferers compared to 
controls (Maycox et al., 2009). Interestingly, overexpression of WNK1 has also been reported to 
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significantly reduce the interaction between endogenous WNK1 and Lingo-1, suggesting that it  may 
serve as a binding platform for Lingo-1, however its kinase activity may not be necessary for Lingo-1 
signaling (Zhang et al., 2009). Furthermore, disruption of the WNK1 gene in mice leads to death of the 
embryo at day 13 (Zambrowicz et al., 2003), suggesting an essential role of WNK1 in embryonic and 
neural development, which is a critical period implicated in a number of neuropsychiatric disorders. 
In support of this hypothesis, a young patient with autism spectrum disorder and a tendency for 
anxiety, has been found to have a 1.5 Mb terminal deletion of the chromosomic region 12p13.33, 
which encompasses the WNK1 gene in its entirety, in addition to 12 other genes (Silva et al., 2014). 
Furthermore, Thevenon et. al.  have shown that a number of patients with either de novo or inherited 
12p13.33 microdeletions, present with not only a number of developmental abnormalities, but also 
with a number of psychiatric disorders including autism spectrum disorder, attention-deficit 
hyperactivity disorder, and anxiety (Thevenon et al., 2013). This is supported by a finding of a 6 Mb 
deletion at 12p13.3 in 2 patients presenting with attention deficit hyperactivity disorder (one of whom 
resided in a psychiatric center) encompassing around 50 genes including WNK1 (Madrigal et al., 
2012). Differential expression of gene transcripts has been found in military personnel suffering from 
traumatic brain injury from blast exposure, who also suffer from post-traumatic stress disorder and 
depression (Heinzelmann et al., 2014). WNK1 was found to be among the genes found to be 
significantly upregulated in these military personnel compared to controls, further implicating WNK1 
in a wider scope of psychiatric disorders. 
Myelin transcription factor 1 (Myt1) and its highly conserved homolog, Myt1-like (Myt1l), are two 
other well-characterized direct intracellular binding partners of Lingo-1. Although disruption of the 
Myt1l gene has been reported in a Dutch schizophrenia population (Vrijenhoek et al., 2008), and 
polymorphisms in the Myt1l gene have been recently reported to be associated with schizophrenia in a 
Chinese Han population, specifically in female schizophrenia subjects (Li et al., 2012), little else is 
known about the implication of the Myt1 gene and protein in schizophrenia. Interestingly, the Myt1 
gene has been predicted to regulate the expression of Neuregulin-1, an extensively studied 
schizophrenia candidate gene, in schizophrenia patients (Law et al., 2006).  Similar to the expression 
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profile of Lingo-1, we have reported significantly higher levels of Myt1 protein in the DLPFC of 
schizophrenia subjects compared to controls, but like Lingo-1, levels of Myt1 were not significantly 
altered in the CA1 or CA3 hippocampal regions (Fernandez-Enright et al., 2014). Considering the role 
of Lingo-1 and Myt1 in oligodendrocyte and myelin dysfunction, it was not surprising to find an 
increase in levels of both these proteins in the DLPFC of schizophrenia patients. Furthermore, both 
Myt1l and Myt1 genes have been further implicated in other neuropsychiatric disorders, including 
autism through a microduplication at 2p25.3 engulfing 7 exons of the terminal portion of Myt1l 
(Meyer et al., 2012) and depression through SNP association (Wang et al., 2010); additionally, 
microduplications in the Myt1l gene have been identified as being present in 2% of childhood onset 
schizophrenia subjects from the same cohort of children who also display 22q11 deletions (Lee et al., 
2012). Further to this, Myt1 has been implicated in mental retardation, through its subtelomeric 
deletion on 20q (Kroepfl et al., 2008), autism spectrum disorder, through a 1.4 Mb copy number 
variation gain at 20q13.33 encompassing the Myt1 gene in its entirety as well as 43 other genes 
(Moessner et al., 2007), in addition to having a potential role in attention deficit hyperactivity 
disorder, demonstrated thorough a genome-wide pathway analyses which identified the cdc25 
pathway of which Myt1 is involved, as being a candidate causal pathway for attention deficit 
hyperactivity disorder (Lee and Song, 2014). 
As mentioned above in section 3.4, Lingo-1 is able to negatively regulate the EGFR/PI3-K/Akt 
signaling pathway (Inoue et al., 2007), also involved in neuronal survival and axon regeneration 
(Brunet et al., 2001). Since Lingo-1 can directly inhibit EGFR independently of EGF activation, 
leading to inhibition of PI3-K/Akt signaling pathways (Inoue et al., 2007); a downregulation of EGFR 
induced by Lingo-1’s inhibitory action may be partly involved in the regional specificity of Lingo-1 
expression in the DLPFC we observed compared to hippocampus in schizophrenia brains (Fernandez-
Enright et al., 2014). In the same post-mortem schizophrenia brain cohort, higher levels of EGFR 
protein in the DLPFC (Brodmann area 46) but not hippocampal regions in schizophrenia versus 
control brains have been reported (Swaminathan et al., 2013). In the context of schizophrenia 
pathophysiology, we postulate that greater levels of EGFR in the DLPFC may play a role in Lingo-1 
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upregulation observed in this region, leading to inhibition of PI3-K/Akt signaling pathways in 
schizophrenia. Moreover, the EGFR/PI3-K/Akt signaling pathway has also been implicated in autism, 
post-traumatic and psychosocial stress disorders, as well as depression through a number of genetic 
and neurobiological studies. EGFR gene regulation was found to be significantly upregulated in the 
same cohort of military personnel suffering blast traumatic brain injury, post-traumatic stress disorder 
and depression as those who also had an upregulation of WNK1 (Heinzelmann et al., 2014). 
Furthermore, both SNP and copy number variation studies have implicated the EGFR/PI3-K/Akt 
signaling pathway in autism spectrum disorders (Cuscó et al., 2009; Toyoda et al., 2007). On the 
biochemical level, the evidence is a little more conflicting; as increased serum levels of EGF have 
been reported in children with autism (İşeri et al., 2011), while in adults with high-functioning autism, 
decreased levels of EGF have been found (Suzuki et al., 2007). This discrepancy suggests that EGF 
plays a differential role in the progression of autism throughout development from childhood through 
to adulthood. Significantly increased levels of EGF were also found in women exposed to prolonged 
psychosocial stress (Åsberg et al., 2009). This is supported by a rodent study which found that Akt 
signaling is significantly increased in the ventral tegmental area in response to stressful stimuli using a 
social defeat paradigm (Krishnan et al., 2008). 
In addition TrkB, another Lingo-1 binding partner, has been implicated in the pathophysiology of 
several psychiatric disorders including drug addiction, schizophrenia, anxiety and bipolar disorders, 
anorexia nervosa and suicide ideation (Gupta et al., 2013). Levels of TrkB mRNA were reported to be 
decreased in the prefrontal cortex from individuals with suicide ideation (Dwivedi et al., 2003) and in 
the hippocampus of patients suffering from schizophrenia and/or mood disorders (Iritani et al., 2003; 
Thompson Ray et al., 2011) compared to healthy controls. Mutations in TrkB have also been linked to 
anxiety disorders (Ernst et al., 2011) as well as susceptibility for nicotine (Beuten et al., 2007) and 
alcohol addiction (Xu et al., 2007). Considering the antagonist effect of Lingo-1 on TrkB receptor-
phosphorylation (Fu et al., 2010), Lingo-1 may play a role in the disturbances of TrkB observed in a 
range of psychiatric disorders, thus emphasizing the importance to further characterize the 
relationship between Lingo-1 and its known and yet to be discovered signaling partners. 
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6. Conclusions and Future Directions 
Little is known about Lingo-1, and it is probably involved in many more neurological disorders that 
we are not yet aware of due to its large range and wide reaching interactions with a variety of proteins 
within the central nervous system. We have provided a large body of evidence demonstrating that 
Lingo-1 signaling pathways are implicated in a wide range of central nervous system neurological 
disorders including spinal cord injury, traumatic brain injury and multiple sclerosis; in addition to 
Parkinson’s disease, essential tremor, Alzheimer’s disease, epilepsy and glaucoma. Furthermore, we 
have provided the first report implicating Lingo-1 and its signaling partner proteins in the 
schizophrenia pathophysiology, and provided sufficient evidence further implicating Lingo-1 
signaling partners in the pathology of a number of neuropsychiatric disorders including autism 
spectrum disorder, depression, attention-deficit hyperactivity disorder, anxiety, drug addiction and 
post-traumatic stress disorder. Due to the role of the many Lingo-1 pathways as a negative regulator 
of myelination and neurite outgrowth, and considering the implication of both of these central 
processes in cognitive performance, antagonists of Lingo-1 appear to be a new potential candidate for 
the treatment of a number of neurological and psychiatric disorders. 
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Figure 1: Schematic representation of Lingo-1 signaling pathways implicated in neurological 
and psychiatric disorders. Oligodendrocyte bound, myelin associated inhibitory proteins - myelin 
associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp) and neurite outgrowth 
inhibitor (Nogo-A) bind to the Nogo Receptor (NgR) with high affinity to inhibit neurite outgrowth 
and myelination processes. NgR lacks a transmembrane domain and requires either the p75 
neurotrophin receptor (p75) or TNF receptor orphan Y (TROY) co-receptors, in addition to Lingo-1 to 
transduce its inhibitory signals. A number of other transmembrane proteins interacting with Lingo-1 
on neurons are also implicated in a wide range of neurological disorders. These include: the epidermal 
growth factor receptor (EGFR) along with its ligand epidermal growth factor (EGF), brain-derived 
neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase B (TrkB), amyloid 
precursor protein (APP), receptor tyrosine-protein kinase erbB-2 (ErbB2), and tropomyosin receptor 
kinase A (TrkA) with its ligand nerve growth factor (NGF). These transmembrane protein-protein 
interactions with Lingo-1 result in the activation of a number of downstream signaling proteins which 
are further implicated in numerous neurological and psychiatric disorders; these include WNK lysine 
deficient protein kinase 1 (WNK1), mitogen activated protein kinase 2/3 (MEK2/3), extracellular 
signal reduced kinase 5 (ERK5), ras homolog gene family, member A (RhoA), phosphatidylinositide 
3-kinase (PI3-K), protein kinase B (PKB, also known as Akt), and finally myelin transcription factor 
1 (Myt1) and its homolog myelin transcription factor 1-like (Myt1l). 
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Evidence for the involvement of Lingo-1 signaling and/or Lingo-1 binding proteins in neurodegenerative and neuropsychiatric disorders. 
Disease Protein(s) Species/Model/Cell Line Study Details Findings Reference 
Alzheimer’s 
Disease 
APP, Lingo-1 Mouse, CD1 Mice underwent time-controlled transcardiac 
perfusion cross-linking (tcTPC) following 
anesthesia. 
 
Interactome maps for APP were obtained by 
immunoprecipitation and two-dimensional 
liquid chromatography and mass 
spectrometry.  
 
Novel interactions between Lingo-1 and APP 
were found in the interactome map. This was 
validated and confirmed by a series of co-
immunoprecipitation experiments using 
antibodies directed at APP or Lingo-1. 
 
In situ hybridization studies showed that 
Lingo-1 and APP are co-localized in the 
mouse brain, with pronounced staining of 
CA1 to CA3 hippocampal neurons. 
 
Bai Y. et. al. 2008 
Alzheimer’s 
Disease 
APP, Lingo-1 Chinese Hamster Ovary 
(CHO) cells 
CHO cells at 90% confluence were transfected 
with APP695 and Lingo-1 constructs. 
 
HA-tagged Lingo-1, and APP constructs were 
co-immunoprecipitated 
APP was co-immunoprecipitated with Lingo-1 
constructs that were lacking either the LRR 
domain or the cytoplasmic domain of Lingo-1. 
 
Co-immunoprecipitation failed with a Lingo-1 
construct comprising only the transmembrane 
and cytoplasmic domain. 
 
Stein T, and 
Walmsley AR. 
2012 
 
 
2 
 
Disease Protein(s) Species/Model/Cell Line Study Details Findings Reference 
The APP interaction with Lingo-1 occurs 
within the Lingo-1 ectodomain, but does not 
require the LRRs. 
 
Alzheimer’s 
Disease 
EGFR Drosophila, Aβ42 transgenic 
flies 
 
Mouse, APP/PS1 double 
transgenic mice 
[strain: B6C3-
Tg(APPswe.PSEN1dE9) 
85Dbo/J] 
Flies underwent a Pavlovian olfactory 
associative immediate memory conditioning 
assay, both before and after being treated with 
EGFR inhibiting drugs Gefitinib and 
Erlotinib. 
 
Mice underwent a 7 day pretesting treatment 
with Gefitinib before being subjected to the 
Morris water maze task for 9 days. 
 
Phospho-EGFR levels were assessed in the 
hippocampus of the mice using western 
blotting. 
Co-expression of EGFR in Aβ42-expressing 
Drosophila exacerbated memory loss; while 
inhibition of EGFR activity prevented 
memory loss in Aβ42-expressing Drosophila. 
 
Treatment with Gefitinib completely 
recovered impaired memory in the APP/PS1 
double transgenic mice. 
 
Phospho-EGFR was elevated in the 
hippocampus of APP/PS1 double transgenic 
mice, and could be suppressed by treatment 
with Gefitinib.  
 
Wang L. et. al. 
2012 
Alzheimer’s 
Disease and 
Spinal Cord 
Injury 
NgR, BDNF Rat, Sprague-Dawley and 
spontaneously hypertensive 
rats (SHR) 
Kainic acid (10 mg/kg i.p.) was administered 
to Sprague-Dawley rats. Rats were decapitated 
and brains removed and frozen at different 
time points post injection for in situ 
hybridization or autoradiography analysis. 
 
SHR rats were given either unlimited access 
or no access to running wheels, and were 
decapitated at different time points after being 
given access to running wheels. 
 
Spinal cord weight drop injuries were 
performed on Sprague-Dawley rats; spinal 
cords were collected at different time points 
after injury. 
 
Kainic acid injections resulted in strong 
downregulation of NgR and strong 
upregulation of BDNF mRNA in dentate 
gyrus, hippocampus and neocortex. 
 
Running on wheels for 3 and 7 days resulted 
in a significant downregulation of NgR mRNA 
in the cortex, hippocampus and dentate gyrus. 
 
No robust regulation of NgR was observed in 
the spinal cord following spinal cord injury. 
Josephson A. et. 
al. 2003 
Alzheimer’s 
Disease 
NgR Human post-mortem brains 
from Alzheimer’s Disease 
subjects 
 
Hippocampal samples were collected from 10 
post-mortem female Alzheimer’s brains and 
10 age-matched non-demented female brains. 
 
Immunohistochemistry and double-labeling 
NgR immunoreactivity was present in more 
than 50% of the pyramidal layer cells of the 
CA1 to CA4 subfields of the hippocampus. 
 
No significant difference in the number of 
Zhu H-Y. et. al. 
2007 
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Disease Protein(s) Species/Model/Cell Line Study Details Findings Reference 
immunofluorescence were used to investigate 
the expression of NgR in the hippocampus of 
Alzheimer’s Disease compared to control 
brains. 
immunopositive cells in the CA1 to CA4 
regions was observed between Alzheimer’s 
and control subjects. 
 
A higher ratio of immunopositive cells to the 
total number of pyramidal cells was observed 
in the CA1 and CA2 hippocampal regions in 
Alzheimer’s brains compared to control 
brains. 
 
Alzheimer’s 
Disease 
NgR, Nogo-A, APP Human post-mortem brains 
from Alzheimer’s Disease 
subjects 
 
Mouse, APPswe/PSEN-
1(ΔE9) double transgenic 
mouse 
 
Human Embryonic Kidney 
HEK-293T cells 
 
APPswe-N2A 
neuroblastoma cells 
Histological analysis of Nogo-A and NgR 
immunoreactivity was performed in post-
mortem sections from the hippocampus and 
Brodmann’s area 20/36 from 6 Alzheimer’s 
brains and 6 control brains. 
NgR localization was assessed in a transgenic 
mouse model of Alzheimer’s disease. 
 
Immunoprecipitation studies were performed 
using the HEK-293T cells to determine 
interactions between Nogo-A and NgR with 
APP. 
 
Western blotting was used to examine 
expression of endogenous NgR and Aβ 
production in the N2A cell line. 
 
APPswe/PSEN-1(ΔE9) double transgenic mice 
were bred with NgR null mice to examine the 
effect of the NgR/ APP interaction in vivo. 
APPswe/PSEN-1(ΔE9) double transgenic mice 
were treated with soluble NgR(310)ecto-Fc 
protein to increase NgR APP interactions in 
vivo.  
 
Nogo-A and NgR are mislocalized in 
Alzheimer’s brain samples. Neither NgR nor 
Nogo-A co-localize with neurofibrillary 
tangles or dystrophic neurites. Results 
confirmed in transgenic mouse model. 
 
APP is physically associated with NgR. 
 
Overexpression of NgR decreases Aβ 
production in N2A neuroblastoma culture. 
 
Targeted disruption of NgR expression 
increases transgenic mouse Aβ levels, Aβ 
plaque deposition and dystrophic neurites. 
 
Infusion of a soluble NgR fragment reduces 
Aβ levels, amyloid plaque deposits and 
dystrophic neurites in a transgenic 
Alzheimer’s disease mouse model. 
Park JH. et. al. 
2006 
Alzheimer’s 
Disease 
Nogo-A, OMgp, 
MAG, NgR, Lingo-
1, TROY 
Rat, Fisher 344 In situ hybridization was used to examine 
mRNA levels of Nogo-A, OMgp, MAG, NgR, 
Lingo-1 and TROY in the cortex and 
hippocampus and young (4 months), middle 
No alterations in levels of NgR, Lingo-1, 
TROY, OMgp or MAG were observed. 
 
Nogo-A was significantly decreased in the 
Trifunovski A. et. 
al. 2006 
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aged (16 months) and old (24 months) rats. hippocampus of the aged rats. 
 
Alzheimer’s 
Disease 
p75 Human post-mortem brains 
from Alzheimer’s Disease 
subjects 
 
Expression of p75 was examined by 
immunocytochemistry in the hippocampus 
taken from the level of the lateral geniculate 
body from 10 female Alzheimer’s Disease 
subjects compared to 10 non-demented 
controls. 
Increased intensity of p75 immunoreactivity in 
cell bodies and processed in the CA1 and CA2 
of Alzheimer’s subjects compared to controls. 
 
Increases in the ratio of p75 expressing 
neurons to thionin (Nissl) stained neurons in 
CA1 and CA2 of Alzheimer’s compared to 
controls. 
 
Large proportion of p75 expressing cells co-
localized with Alz-50 (recognizes tau protein) 
in CA1 and CA2 regions in Alzheimer’s 
Disease subjects. 
 
Hu X-Y. et. al. 
2002 
Autism BDNF, TrkB, PI3-
K, Akt, mTOR, p75 
Human post-mortem brains 
from autism subjects 
 
Rat, Valproic acid (VPA) – 
induced rat model of autism 
Protein levels were examined by western blot 
in the fusiform gyrus of 11 autism and 13 
control subjects and in the lateral temporal 
neocortices of VPA rats and control rats. 
Decreased TrkB, PI3K, Akt, mTOR and 
phospho-mTOR protein levels in autism 
compare to controls. 
 
Trending increase in truncated TrkB and p75 
protein levels in autism compare to controls. 
 
Similar results observed in VPA rats. 
 
Fahnestock M, 
and Nicolini C. 
2014 
Autism EGF Human Blood serum levels of EGF were examined by 
sandwich ELISA in 27 autistic children and 28 
age-matched controls (age 2-11 years) 
 
 
Increased levels of EGF serum levels in 
autistic children compared to controls. 
İşeri E. et. al. 
2011 
Autism EGF Human, Japanese Blood serum levels of EGF were examined by 
ELISA in 17 male autistic subjects and 18 
age-matched control subjects (aged 19-28 
years). 
 
 
Decreased serum levels of EGF in high-
functioning autism subjects compared to 
controls. 
Suzuki K. et. al. 
2007 
Autism EGF Human, Caucasian Genetic association study using 252 White trio 
families with a male offspring scored for 
autism. Hispanic and Latino families were 
A significant haplotypic association between 
EGF gene and autism. 
 
Toyoda T. et. al. 
2007 
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excluded. The rs4698803 and rs6533485 SNPs showed a 
tendency towards an association with autism. 
 
Autism Lingo-1 Human Genetic screening for copy number variants 
across 15q24 was performed on 173 unrelated 
subjects with autism spectrum disorder. 
Additionally 1336 subjects with autism 
spectrum disorder from 785 families were also 
screened. 
Results were confirmed by array comparative 
genomic hybridization and quantitative PCR. 
An atypical de novo deletion of 3.06 Mb in 
15q23-24.1 was discovered in a boy with 
autism. He shared many features with the 
other 13 subjects with 15q24 microdeletion 
syndrome that have been described to date. 
 
Deletions in 15q24 represent rare causes of 
autism spectrum disorder. 
 
McInnes LA. et. 
al. 2010 
Autism Myt1l Human Subjects were male half-siblings born to a 
common mother by different fathers. Both 
subjects score well above the cut-off for 
autism on the Autism Diagnostic Interview-
Revised (ADI-R). 
 
The 2p25.3 duplication was identified in both 
male siblings using an Affymetrix 10K SNP 
microarray.  
 
Duplication of 2p25.3 was confirmed using 
fluorescence in situ hybridization, and 
Affymetrix 6.0 SNP arrays were used to more 
precisely delineate the duplication 
breakpoints. 
 
Fluorescence in situ hybridization revealed 
evidence for duplication in both affected half-
brothers. 
 
Their mother tested positive for duplication of 
33-40% of the fluorescence in situ 
hybridization probes, revealing that she was 
mosaic in her lymphoblasts for the 
duplication. 
 
Affymetrix 6.0 revealed that the 2p25.3 
duplication was approx. 281 kb and that only 
63 kb of the Myt1l terminus (containing 7 
exons) was duplicated. 
Meyer KJ. et. al. 
2012 
Autism p75 Mouse, Purkinje cell-
selective p75 knockout mice 
(Cre-loxP mice) 
Immunohistochemistry was used to examine 
quantitative microanatomy of the Purkinje 
cells in the mice by genotype. 
 
Locomotor activity and social interaction were 
assessed. 
Cre-loxP mice exhibit complete knockout of 
p75 in approx. 50% of their cerebellar 
Purkinje cells. 
 
Cre-loxP mice display decreased 
allogrooming, socialization and fighting with 
other mice. 
 
Cre-loxP mice display decreased non- 
ambulatory exploration of their environment 
than wild types; and display increased 
Lotta LT. et. al. 
2014 
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jumping behavior compared to wild-types. 
 
Autism PI3-K Human, Caucasian A comparative genomic hybridization array 
was performed on a cohort of 96 Spanish 
patients with idiopathic autism spectrum 
disorder. 
238 copy number variations were detected, 
and of these, 13 were present specifically in 
the autistic population (i.e. 12 out of the 96 
individuals) 
 
Cuscó I. et. al. 
2009 
Autism WNK1 Human An 8-year old boy of European origin 
presented for evaluation of 
neurodevelopmental delay. G-banded 
chromosome analysis was performed on 
peripheral blood lymphocytes. Array 
comparative genomic hybridization was 
performed on DNA extracted from peripheral 
blood using a whole-genome, bacterial 
artificial chromosome-based microarray. 
 
Comparative genomic hybridization revealed 
a 1.5 Mb terminal deletion at 12p13.33, 
encompassing 13 different genes: B4GALNT3, 
CCDC77, ERC1, FBXL14, IQSEC3, KDM5A, 
LINC00942, LOC574538, NINJ2, RAD52, 
SLC6A12, SLC6A13 and WNK1. 
Silva IMW. et. al. 
2014 
Autism, 
Attention 
Deficit 
Hyperactivity 
Disorder and 
Anxiety 
WNK1 Human A genetic study was performed on a series of 
9 patients with 12p subtelomeric deletions, 
including 2 familial cases with severs speech 
sound disorders. 
 
The Human Genome CGH Microarray 44, 
105, 180 or 244K from Agilent Technologies 
was utilized for analysis and fluorescence in 
situ hybridization and quantitative PCR were 
used to confirm results. 
 
Subjects with either inherited or de novo 
12p13.33 microdeletions present with 
developmental abnormalities, in addition to 
psychiatric disorders including autism 
spectrum disorder, attention-deficit 
hyperactivity disorder and anxiety. 
Thevenon J. et. al. 
2013 
Essential 
Tremor 
Lingo-1 Human A meta-analysis was conducted on 11 
association studies between Lingo-1 
rs9652490 (3972 cases vs. 20714 controls), 
and 7 association studies between Lingo-1 
rs11856808 (2076 cases vs. 18792 controls) 
and their risk for essential tremor. 
There is a significant relationship between 
Lingo-1 rs11856808 and essential tremor and 
familial essential tremor. 
 
The Lingo-1 rs9652490 polymorphism was 
only related to a familial risk for essential 
tremor. 
 
Jiménez-Jiménez 
FJ. et. al. 2012 
Essential 
Tremor 
Lingo-1 Human post-mortem brains 
from essential tremor 
subjects 
Post-mortem tissue was obtained from 
essential tremor patients and age-matched 
controls. 
Western blotting showed that Lingo-1 protein 
was significantly increased in the cerebellar 
cortex of essential tremor brains compared to 
Kuo S-H. et. al. 
2013 
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Western blotting (using10 essential tremor 
cases and 11 controls) and 
immunohistochemistry (11 essential tremor 
and 12 controls) were used to examine ingo-1 
protein in essential tremor compared to 
control brains. 
 
controls; however levels were similar in the 
occipital cortex. 
 
Immunohistochemistry revealed that Lingo-1 
was enriched in the distal axonal processes of 
basket cells, forming a pinceau structure 
around the Purkinje cell axon initial segment. 
 
Essential 
Tremor 
Lingo-1 Human, Caucasian Genome-wide association study was 
conducted on Icelandic subjects with essential 
tremor. 
 
Illumina HumanHap300 and HumanCNV370 
chips were used. 
rs9652490 and rs11856808 SNPs were both 
found to be significantly associated with 
essential tremor. 
 
Only the rs9652490 SNP was found to be 
significant at the genome-wide level. 
 
Stefansson H. et. 
al. 2009 
Essential 
Tremor and 
Parkinson’s 
Disease 
Lingo-1 Human, Caucasian The cohort from this study included: 356 
essential tremor patients from North America, 
426 Parkinson’s disease patients form North 
America, 618 Parkinson’s disease patients 
from Norway; in addition to 428 controls from 
North America and 602 controls from 
Norway. All subjects were of Caucasian 
descent. 
 
Genotyping was performed using a TaqMan 
probe on an ABI7900. 
 
There was a significant association between 
the Lingo-1 SNP rs9652490 and both essential 
tremor and Parkinson’s disease. 
Vilariño-Güell C., 
Ross OA. et. al. 
2010 
Essential 
Tremor and 
Parkinson’s 
Disease 
Lingo-1 Human, Caucasian A total of 1247 essential tremor patients, 633 
Parkinson’s disease patients, and 642 control 
subjects were used in this study. All subjects 
were Caucasian and from North America. 
 
Genomic DNA was extracted from peripheral 
blood lymphocytes and Lingo-1 and Lingo-2 
genes were sequenced in 95 essential tremor 
and 96 Parkinson’s disease patients (randomly 
selected). 
 
Haplotype-tagging SNPs identified by 
Sequencing revealed 6 novel coding variants 
in Lingo-1 (S4C, V107M, A277T, R423R, 
G537A, and D610D), in addition to 5 known 
polymorphisms (rs2271398, rs2271397, 
rs2271396, rs3743481, and rs61737308). 
 
The Lingo-1 SNPs S4C, A277T, R423R, 
G537A and D610D were observed exclusively 
in cases (either essential tremor or both 
essential tremor and Parkinson’s disease) and 
not in controls. 
 
Vilariño-Güell C., 
Wider C. et. al. 
2010 
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sequencing were genotyped using a Sequenom 
MassArray iPLEX platform. 
Associations with essential tremor were also 
observed for Lingo-1 SNPs rs4886887, 
rs3144, rs8028808 and rs12905478; with 
rs4883887 and rs3144 being driven by the 
minor alleles. 
 
The Lingo-1 SNP rs907396 was associated 
with a 5-year younger mean age of onset of 
essential tremor. 
 
Glaucoma Lingo-1, RhoA, 
PI3-K, Akt 
Rat, Sprague-Dawley An experimental ocular hypertension model in 
female rats was used. 
 
Lingo-1 expression in retinas was investigated 
using immunohistochemistry and western 
blotting. 
 
Soluble Lingo-1 (Lingo-1-Fc) and anti-Lingo-
1 antibody (mAb 1A7) were injected into 
vitreous body to examine effects of Lingo-1 
antagonism on RGC survival after ocular 
hypertension and optic nerve transection. 
 
Lingo-1 was expressed in RGCs and up-
regulated after intraocular pressure elevation. 
 
Blocking Lingo-1 using Lingo-1-Fc, 
significantly reduced RGC loss both 2 and 4 
weeks after ocular hypertension and promoted 
RGC survival after optic nerve transection. 
 
Lingo-1-Fc and mAb 1A7 treatment blocked 
the RhoA pathway and promoted Akt 
activation. 
Fu Q-L. et. al. 
2008 
Glaucoma Lingo-1, BDNF, 
TrkB 
Rat, Sprague-Dawley Experimental ocular hypertension model in 
rats was used to examine whether BDNF 
combined with Lingo-1 antagonists can 
promote long-term RGC survival after ocular 
hypertension. 
 
Immunohistochemistry and western blotting 
were used to assess TrkB and Lingo-1 
expression. 
BDNF alone shows slight neuroprotection to 
RGCs 4 weeks after ocular hypertension. 
 
Combined BDNF and Lingo-1-Fc treatment 
prevents RGC death in the same condition. 
 
Lingo-1 is co-expressed with BDNF receptor 
TrkB in the RGCs 
 
BDNF combined with Lingo-1-Fc activated 
more TrkB in the injured retina compared to 
BDNF alone. 
 
Fu Q-L. et. al. 
2009 
Glaucoma Lingo-1, NgR, 
Myocilin 
Mouse, Myocilin-null mice 
(Myoc-null mice) 
Myocilin-null mice were compared to wild 
type mice in all experiments. 
 
Myocilin is expressed and secreted by optic 
nerve astrocytes. 
 
Kwon HS. et. al. 
2014 
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Quantitative PCR, immunoprecipitation, 
western blotting, immunohistochemistry and 
co-immunoprecipitation experiments were 
used to examine the role of Myocilin in the 
optic nerve and the interaction of Myocilin 
with the NgR/Lingo-1 complex.  
Differentiation of optic nerve 
oligodendrocytes is delayed in Myocilin-null 
mice. 
 
Optic nerves of Myocilin-null mice contain 
reduced levels of MBP, myelin proteolipid 
protein and 2’3’-cyclic nucleotide 3’-
phosphodiesterase compared to wild types. 
Myocilin-null mice have reduced myelin 
sheath thickness on optic nerve axons 
compared to wild types. 
 
Myocilin stimulates oligodendrocyte 
differentiation through the NgR/Lingo-1 
receptor complex. 
 
Myocilin interacts physically with Lingo-1 
and may be considered to be a Lingo-1 ligand. 
 
Glaucoma Lingo-1, TrkB, 
BDNF 
Rat, Sprague-Dawley 
 
Human Embryonic Kidney 
HEK-293T cells 
overexpressing both Lingo-1 
and TrkB  
Adult female Sprague-Dawley rats underwent 
a laser eye procedure to induce unilateral 
ocular hypertension. 
 
Lingo-1-Fc or 1A7 (2 μg in 2μL PBS) were 
administered intravitreally to the rats on Day 
0, then anti-BDNF (1 μg/μL) was injected into 
the experimental eye on Day 0 (30 min after 
1A7 or Lingo-1-Fc injection), then at 4, 7 and 
10 days after laser treatment. 
 
Immunoprecipitation studies using both HEK-
293T cells and cells from injured retinas were 
conducted to assess if TrkB and Lingo-1 form 
an interacting complex. 
 
BDNF and TrkB expression levels in the rat 
retinas were assessed by western blotting. 
 
Retinal levels of BDNF were quantified by 
Lingo-1 forms a receptor complex with TrkB 
and negatively regulates its activation in the 
retina after ocular hypertension injury. 
 
Lingo-1 antagonists 1A7 antibody or Lingo-1-
Fc treatment up-regulates phospho-TrkB 
activation and leads to RGC survival after 
ocular hypertension injury. 
 
Treatment with an anti-BDNF antibody blocks 
the neuronal protective effect of the Lingo-1 
antagonists. 
 
Blocking Lingo-1 promotes the activation of 
TrkB after the induction of ocular 
hypertension. 
Fu Q-L. et. al. 
2010 
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ELISA. 
 
BDNF-positive RGCs in the retina were 
quantified by immunohistochemistry. 
 
Glaucoma NgR Rat, Sprague-Dawley 
 
Adult female Sprague-Dawley rats were 
subjected to either a laser eye procedure to 
induce unilateral ocular hypertension, or an 
optic nerve transection procedure. 
 
After the first laser eye procedure or 
immediately following optic nerve transection, 
an intravitreal injection of soluble sNgR-Fc 
(2μg in 2 μL PBS) was given. 
 
Rats were sacrificed at 5 days, 2 weeks or 4 
weeks in the ocular hypertension model and at 
1 week in the optic nerve transection model. 
Rats in the 4 week group received treatments 
once per week. 
 
Expression of NgR in the normal and injured 
rat retina was assessed by 
immunohistochemistry. 
 
The effect of sNgR-Fc on synaptic input after 
the induction of ocular hypertension was 
assessed by immunohistochemical analysis of 
c-Fos expression. 
 
Retinal NgR expression was measured by 
western blotting. 
 
NgR was expressed in RGCs and was 
upregulated after intraocular pressure 
elevation. 
 
Treatment with soluble sNgR-Fc significantly 
reduced RGC loss at both 2 and 4 weeks after 
the induction of ocular hypertension. 
 
sNgR-Fc treatment promoted RGC survival 
after optic nerve transection. 
 
sNgR-Fc attenuated synaptic degeneration at 5 
days, 2 weeks and 4 weeks. 
Fu Q-L. et. al. 
2011 
Major 
Depression 
Myt1l Human, Chinese Han A total of 1139 major depressive patients (487 
males and 652 females) and 1140 controls 
(374 males and 766 females) were genotyped 
from a Chinese Han population. 
 
8 tag SNPs were genotyped (rs1617213, 
3 SNPs were found to have significant allelic 
and genotypic associations with major 
depressive disorder (rs3748989, rs3748988 
and rs7592630). 
 
After correction by SNPSpD rs3748989 
Wang T. et. al. 
2010 
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rs6759709, rs6727410, rs11687068, 
rs3748989, rs3748988, rs4305302 and 
rs7592630), using the ABI 7900 DNA 
detection system with Taq-Man probes from 
Applied Biosystems. 
 
retained genotypic and allelic significance, 
and rs3748988 retained genotypic 
significance. 
Major 
Depression 
TROY 
(TNFRSF19) 
Human Fibroblasts Cultured dermal fibroblast samples from 
patients with major depressive disorder and 
matched controls were assayed for genome-
wide mRNA expression using an Agilent 2100 
Bioanalyzer microarray assay. Results were 
validated by quantitative PCR.  
 
Quantitative PCR was also used to assess over 
1000 microRNA (miRNA) species. 
Fibroblasts from major depressive patients 
showed a strong mRNA expression pattern 
change in molecular pathways including cell-
to-cell communication, innate/adaptive 
immunity, and cell proliferation. 
 
The same fibroblasts showed altered 
expression of a distinct panel of 38 miRNAs. 
 
TNFRSF19 mRNA is downregulated in 
fibroblasts from major depressive disorder 
patients compared to matched healthy 
controls. 
 
Garbett KA. et. al. 
2014 
Megalencephaly BDNF, TrkB, 
Nogo-A, Lingo-1, 
NgR, TROY, 
OMgp 
Mouse, BALB/cByJ-
Kv1.1
mceph/mceph
 
BALB/cByJ-Kv1.1
mceph/mceph
 (also known as 
mceph/mceph) mice and wild type mice were 
treated with carbamazepine (3.5 g/kg pellets) 
from postnatal week 6 to 12. The expected 
daily intake of carbamazepine was 0.5 g/kg 
body weight per rat. 
 
Levels of BDNF, TrkB, Nogo-A, Lingo-1, 
NgR, TROY, and OMgp mRNA were assessed 
by in situ hybridization in mceph/mceph mice 
compared to wild types along with the effects 
of carbamazepine treatment on mRNA levels. 
BDNF mRNA was significantly increased in 
the CA3, ventral cortex, amygdala and CA1 of 
mceph/mceph mice compared to wild types. 
 
TrkB mRNA was significantly upregulated in 
the dentate gyrus of mceph/mceph mice 
compared to wild types. 
 
Nogo-A mRNA hybridization was increased in 
the CA3 of mceph/mceph mice compared to 
wild types. 
NgR mRNA was increased in the dentate 
gyrus in mceph/mceph mice compared to wild 
types. 
 
Lingo-1 mRNA was increased in the CA3, 
dentate gyrus, ventral cortex and amygdala in 
mceph/mceph mice compared to wild types. 
 
Lavebratt C. et. 
al. 2006 
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TROY mRNA was decreased in the cortex, 
dentate gyrus CA1 and ventral cortex of 
mceph/mceph mice compared to wild types. 
 
OMgp mRNA levels were upregulated in the 
amygdala of mceph/mceph mice compared to 
wild types. 
 
Treatment with carbamazepine completely 
normalized all of the dysregulations in the 
expression of BDNF, Nogo-A, NgR, Lingo-1 
and TROY mRNA in the mceph/mceph mice. 
TrkB and OMgp levels were not normalized 
by carbamazepine treatment. 
 
Multiple 
Sclerosis 
Lingo-1 Mouse, myelin 
oligodendrocyte 
glycoprotein-induced 
experimental autoimmune 
encephalomyelitis (EAE) 
mice; created from C57/BL6 
mice 
Lentiviral vectors encoding Lingo-1 short 
hairpin RNA (LV/Lingo-1-shRNA) were 
constructed to inhibit Lingo-1 expression. 
 
EAE mice received intracerebroventricular 
injections (5μL) of LV/Lingo-1shRNA into 
both lateral ventricles over a 5 min time 
period followed by an additional 2 min delay 
to allow for diffusion before removal of the 
cannula. 
 
Locomotor activity was assessed at different 
time points (1, 3, 7, 14, 21 and 30 days after 
injection). 
 
Levels of myelination were examined by luxol 
fast blue staining. 
 
Lingo-1 mRNA and protein expression were 
examined from cortical samples by real-time 
PCR and western blotting respectively. 
 
Lingo-1 mRNA and protein expression was 
higher in untreated EAE mice compared to 
wild types at all time points examined. 
 
Lingo-1 mRNA and protein levels were 
significantly downregulated by LV/Lingo-1-
shRNA treatment compared to the untreated 
EAE mice. 
 
Locomotor activity scores were significantly 
lower in the LV/Lingo-1-shRNA treated 
groups than in the untreated mice. 
 
Significant demyelination was observed in the 
EAE mice compared to the wild type mice. 
LV/Lingo-1-shRNA treatment resulted in 
significantly higher myelination than the 
untreated group, but myelination levels 
remained lower than in the wild type mice. 
Wang C-J. et. al. 
2014 
Multiple 
Sclerosis 
Lingo-1 Human, Caucasian The cohort used for this study consisted of 
293 unrelated Caucasian Spanish patients (203 
Lingo-1 SNPs rs9652490 and rs11856808 
were found not to have any significant allelic 
García-Martín E. 
et. al. 2013 
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females and 90 males, average age 43.9±11.4) 
and 318 healthy, unrelated controls (221 
females and 97 males, average age 43.7±12.4), 
matched for age and gender. 
 
Genomic DNA was obtained from peripheral 
leukocytes and the Lingo-1 SNPs rs9652490 
and rs11856808 were genotypes using 
KASPar assays. 
 
or genotypic associations with multiple 
sclerosis. 
 
Allelic and genotypic frequencies were found 
to be unrelated to the age of onset of multiple 
sclerosis, gender and the clinical course of the 
disease. 
Multiple 
Sclerosis 
Lingo-1 Human Two separate randomized, placebo-controlled 
Phase 1 clinical trials were performed. Single 
ascending doses (0.1 to 100 mg/kg) and 
multiple ascending doses (0.3 to 100 mg/kg; 2 
doses separated by 14 days) of BIIB033 or 
placebo were administered intravenously to 64 
healthy adult volunteers and 42 subjects with 
relapsing-remitting or secondary progressive 
multiple sclerosis respectively. 
 
Safety assessments included adverse event 
monitoring, neurologic examinations, 
conventional and non-conventional MRI, 
EEG, optical coherence tomography, retinal 
examinations and evoked potentials. 
 
Serum and cerebrospinal fluid samples were 
collected to measure BIIB033 concentrations. 
 
BIIB033 infusions were well tolerated. 
 
The frequency of adverse effects was similar 
between BIIB033 and placebo; headache was 
the most frequently reported adverse effect. 
 
Doses at 10 mg/kg or higher resulted in 
BIIB033 concentrations similar to or higher 
than the concentration associated with 90% of 
the maximum remyelination effect in rats. 
Tran J. et. al. 
2014 
Multiple 
Sclerosis 
Lingo-1 Rat, myelin oligodendrocyte 
glycoprotein-induced 
experimental autoimmune 
encephalomyelitis (EAE) 
rats 
 
Mouse, Lingo-1 knockout 
Myelin oligodendrocyte glycoprotein-induced 
experimental autoimmune encephalomyelitis 
(EAE) was induced in both mice and rats 
(Lingo-1 knockout mice vs. wild type 
C57BL6J mice, and Sprague-Dawley rats). 
 
3 days after EAE induction, rats were treated 
with either intrathecal injections of either an 
isotype control antibody, or anti-Lingo-1 (185 
mg/day for 2 weeks); or intraperitoneal 
Lingo-1 knockout mice have an earlier onset 
of myelination compared to wild-types. 
 
While both wild-type and Lingo-1 knockout 
mice displayed EAE symptoms, the EAE 
scores were significantly higher in Lingo-1 
knockout mice. 
 
Electron microscopy showed that lower EAE 
scores reflect remyelination. 
Mi S. et. al. 2007 
 
 
14 
 
Disease Protein(s) Species/Model/Cell Line Study Details Findings Reference 
injections of the same antibodies (8mg/kg 
twice per week for 2 weeks). 
 
Lingo-1 knockout and wild-type control mice 
also underwent EAE induction. 
 
All animals were perfused 30-36 days after 
EAE induction and spinal cord tissues were 
prepared for diffusion tensor imaging, 
immunocytochemistry and electron 
microscopy analysis to assess the levels of 
de/re-myelination in the different treatment 
groups. 
 
Lingo-1 knockout EAE animals showed an 
abundance of newly formed myelin sheaths, 
and had more myelinated fibers overall 
compared to wild-type EAE mice.  
 
Blocking Lingo-1 function either by gene 
knockout or though treatment with an anti-
Lingo-1 antibody, promotes functional 
recovery in the EAE model. 
 
Functional recovery is correlated with 
improved axonal integrity and axonal 
myelination. 
 
Demyelination in the spinal cord of anti-
Lingo-1 treated EAE rats was five times lower 
than in the control group. 
 
More myelination and/or remyelinated axons 
were found in anti-Lingo-1 treated rats. 
 
Multiple 
Sclerosis 
Lingo-1, TROY, 
p75, NgR 
Human post-mortem brains 
from multiple sclerosis 
subjects 
Post-mortem brain samples from the frontal 
cerebral cortex or the cerebellar cortex were 
obtained from autopsied brains from 5 
multiple sclerosis patients and 10 non-multiple 
sclerosis cases. 
 
Immunoreactivity and protein expression 
levels were assessed for both Lingo-1 and 
TROY proteins by immunohistochemistry and 
Lingo-1, TROY, p75 and NgR proteins by 
western blot respectively. 
Immunohistochemistry revealed that Lingo-1 
and TROY are expressed in the cerebral 
cortex, brainstem and spinal cord from both 
multiple sclerosis and non-multiple sclerosis 
brains; and that this expression is in neurons, 
reactive astrocytes, and 
macrophages/microglia, but not 
oligodendrocytes. 
 
Western blot revealed overall higher levels of 
TROY expression in multiple sclerosis brains 
compared to non-multiple sclerosis brains., 
whereas Lingo-1 levels were found to be 
reduced in all multiple sclerosis cases. 
 
Expression pattern of p75 was generally the 
same as that of TROY, and NgR showed a 
Satoh J. et. al. 
2007 
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trend for higher levels in the cerebellum vs. 
lower levels in the cerebrum. 
 
Multiple 
Sclerosis 
Lingo-1, RhoA Primary cell culture, dorsal 
root ganglion (DRG) 
neurons from E14-17 Long 
Evans rats 
 
Rat, Long Evans 
 
Mouse, Lingo-1 knockout 
Primary dorsal root ganglion (DRG) cell 
cultures of embryonic E14-17 Long Evans rats 
were grown in vitro for testing with: Lingo-1-
Fc, dominant-negative (DN)-Lingo-1, full-
length (FL)-Lingo-1 or Lingo-1 RNAi.  
 
The number of total and mature 
oligodendrocytes was quantified by western 
blot analysis and electron microscopy. 
 
Myelinated axons in the 2-week-old cultures 
were quantified by counting the number of 
myelinated internode bundles that were 
derived from single MBP
+
 oligodendrocytes. 
 
Immunohistochemistry was used to examine 
expression of O4, MBP, CNPase, and Lingo-1 
in tissue sections from mice and in cell 
cultures. 
 
Lingo-1 expression was examined in rat optic 
nerve sections by in situ hybridization. 
 
mRNA extracted from rat brains was 
subjected to RT-PCR to quantify Lingo-1 
mRNA. 
 
Oligodendrocyte progenitor cells were treated 
for 2 days with Lingo-1-Fc or control-Fc. 
RhoA-GTP and RhoA amounts were 
quantified. 
 
Expression levels of the myelin proteins MBP 
and MAG in cells were determined by western 
blotting. 
 
RT-PCR in purified populations of CNS cells 
showed Lingo-1 is expressed highly in 
neurons, a low expression in 
oligodendrocytes; however it is not expressed 
in astrocytes. 
 
In situ hybridization and 
immunohistochemistry in sections from adult 
optic nerve tissue confirmed the expression of 
Lingo-1 in oligodendrocytes. 
 
RT-PCR showed that Lingo-1 RNAi infected 
oligodendrocytes had reduced levels of 
endogenous Lingo-1 expression. This 
reduction in Lingo-1 resulted in more highly 
differentiated and mature oligodendrocytes, 
increased length of cell processes and more 
abundant myelin sheath structures. 
 
DN-Lingo-1 infected oligodendrocytes 
showed increased differentiation and resulted 
in a five-fold increase in the number of mature 
oligodendrocytes; in addition to a five-fold 
increase in the amount of MBP expressed. 
 
Overexpression of FL-Lingo-1 inhibited 
differentiation; the cells had less developed 
processes and an 80% reduction in the number 
of mature oligodendrocytes. Additionally, 
these cells also displayed 90% lower amounts 
of MBP expressed. 
 
A2B5
+
 oligodendrocyte progenitors treated 
with Lingo-1-Fc differentiated into mature 
oligodendrocytes in a concentration dependent 
manner. The treatment also resulted in 
Mi S. et. al. 2005 
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DRG neuron and oligodendrocyte cultures 
were grown for 4 weeks in the presence of 
Lingo-1-Fc (10 μg/ml) or control-Fc.  
 
Ultrastructural analysis of spinal cords from 
Lingo-1 knockout mice and the DRG cultures 
was performed using electron microscopy. 
oligodendrocytes with longer processes and 
more abundant myelin sheaths. 
 
Treatment of oligodendrocytes with Lingo-1-
Fc, DN-Lingo-1 or Lingo-1 RNAi resulted in 
reduced levels of RhoA. 
 
Lingo-1-Fc and DN-Lingo-1 treatment on 
oligodendrocyte and neuron co-cultures 
resulted in concentration dependent robust 
axonal myelination. MAG, MOG, OMgp, 
CNPase and MBP were also upregulated. 
Furthermore FL-Lingo-1 decreased MBP 
expression by 50%. 
 
Primary cell cultures from Lingo-1 knockout 
mice have more highly differentiated and a 
larger percentage of mature oligodendrocytes 
than wild-type cultures.  
 
Spinal cords from Lingo-1 knockout mice 
contained more myelinated fibers than wild-
type spinal cords. 
 
Multiple 
Sclerosis 
Lingo-1 Rat, myelin oligodendrocyte 
glycoprotein-induced 
experimental autoimmune 
encephalomyelitis (EAE) 
rats 
 
Rat, oligodendrocyte 
cultures, dorsal root 
ganglion (DRG) neuron 
cultures, co-culture 
myelination assays and 
oligodendrocyte 
differentiation assays 
 
Rat, Sprague-Dawley 
1A7 or isotype control antibody (4 μg) was 
injected intravitreally into the right eye of 
EAE rats from disease onset for 2 weeks. 
 
Oligodendrocyte cultures, dorsal root ganglion 
(DRG) neuron cultures, co-culture 
myelination assays and oligodendrocyte 
differentiation assays were prepared. 
 
300 μm sections were taken from the brains of 
PN2 mice at the junction of the corpus 
callosum to the hippocampus. Sections were 
cultured in serum containing either anti-
Lingo-1 (10 μg/ml) or control antibody for 4 
days.  
Optic nerves of antibody treated EAE rats 
showed evidence of extensive myelination 
compared to rats treated with control 
antibody; myelin sheaths of treated rats were 
thinner than those in untreated rats, suggesting 
that they were remyelinated. 
 
1A7 antibody treatment produced robust 
myelination in co-cultures of DRG and OPCs 
compared to treatment with the isotype 
antibody control. Western blotting showed a 
dose dependent increase in MBP expression in 
the co-cultures treated with the 1A7 antibody. 
 
Incubation of P2 forebrain slices with 1A7 
Mi S. et. al. 2009 
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Mouse, C57BL/6 
 
Mouse, Lingo-1 knockout 
 
Sagittal cerebellar slices were taken from 
PN10 rats and grown for 7 days before 
treatment with 5 mg/ml 
lysophosphatidylcholine (LPC) to induce 
demyelination. Slices were then incubated 
with 1A7 or control antibody (10 μg/ml) for 3 
days, and remyelination was visualized by 
MBP immunostaining. 
 
Rats received direct injections of LPC into the 
spinal cord, followed 3 days later by treatment 
with 1A7 or control antibody (1.5 μg in 2 μl). 
LPC-treated rat spinal cords were sectioned 
and toluidine blue staining and electron 
microscopy were used to assess levels of 
remyelination versus demyelination. 
 
Immunohistochemistry was used to visualize 
myelination with anti-MBP, oligodendrocyte 
precursor cells (OPCs) with anti-NKx2.2 and 
Lingo-1 positive (Lingo-1
+
) OPCs with anti-
Lingo-1 in the lesions of 1A7 antibody and 
control treated rats. 
 
Cuprizone treated mice received stereotaxic 
injections of 1A7 of isotype control antibody 
at weeks 2.5 and 3 of cuprizone feeding. Mice 
were euthanized 4 and 6 weeks after antibody 
injection. 
 
Lingo-1 knockout and wild-type mice also 
received cuprizone treatment for 4 weeks to 
assess the number of myelinated axons.  
for 4 days resulted in approximately 30-fold 
increased staining of MBP-positive cells and 
20-fold increase in myelinated axon clusters 
distributed in the periventricular area and 
cerebral cortex. 
 
Exposure to 1A7 antibody for 3 days after 
removal of LPC from P10 cerebellar slices 
resulted in an extensive reorganization of the 
MBP
+ 
fibers which had previously been 
punctuated and disorganized by the LPC. 
 
Lingo-1 was strongly expressed in OPCs 
compared with mature oligodendrocytes, and 
increased numbers of Lingo-1
+
 cells were seen 
in 7-day post-LPC spinal cord lesions. The 
number of NKx2.2
+ 
and Lingo-1
+
 cells was 
also increased in the lesions. Toluidine blue 
stained sections and electron microscopy 
showed a three-fold increase in myelinated 
fibers in 1A7-treated animals compared with 
control animals. 
1A7-treated lesions displayed less Lingo-1
+ 
OPCs and more mature MBP
+
 
oligodendrocytes than antibody controls; 
treatment with Lingo-1 antagonists also 
enhanced re-myelination in the LPC rat and 
slice models. 
 
Cuprizone treated mice that also received 1A7 
treatment showed substantially more MBP 
staining, indicative of increased myelin, than 
control treated mice. This was confirmed by 
ultrastructural analysis by electron 
microscopy. 
 
Lingo-1 knockout mice had significantly more 
myelinated axon fibers after 4 weeks of 
cuprizone treatment compared to wild-types. 
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Multiple 
Sclerosis 
Nogo-A, NgR, p75, 
APP 
Human post-mortem brains 
from multiple sclerosis 
subjects 
Post-mortem brain samples from the frontal 
cerebral cortex or the cerebellar cortex were 
obtained from autopsied brains from 4 
multiple sclerosis patients, 6 non-multiple 
sclerosis cases with 
neurologic/neuropsychiatric disorders, and 6 
neurologically normal cases. 
 
Immunoreactivity and protein expression 
levels were assessed for Nogo-A, NgR, APP 
and p75 proteins by immunohistochemistry 
and Nogo-A and NgR proteins by western blot 
respectively. 
Immunohistochemistry revealed a substantial 
number (20%-60%) of surviving 
oligodendrocytes and remaining myelin 
sheaths in multiple sclerosis cases expressed 
intense levels of Nogo-A. Adjacently stained 
sections revealed that APP reactive axons 
were hardly detectable in any case examined, 
and that these axons did not co-localize with 
Nogo-A expressing oligodendrocytes. 
 
Immunohistochemistry also showed that a 
large number (>60%) of astrocytes, microglia 
and neurons have an intense immunoreactivity 
for NgR. 
 
p75 was most prominently expressed in the 
nerve fibers of substantia gelatinosa in the 
spinal cord, tractus solitaries in the brain stem 
and the vascular wall of the cerebrum. p75 
was not expressed on oligodendrocytes, 
astrocytes or microglia/macrophages. 
 
Satoh J-I. et. al. 
2005 
Multiple 
Sclerosis 
Nogo-A, NgR Mouse, myelin 
oligodendrocyte 
glycoprotein-induced 
experimental autoimmune 
encephalomyelitis (EAE) 
C57BL/6 mice 
Myelin oligodendrocyte glycoprotein-induced 
experimental autoimmune encephalomyelitis 
(EAE) was induced in C57BL6J mice. 
Mice were euthanized at 4 different time 
points (Day 0 – naïve, Day 10 – preclinical, 
Days 18-22 – acute, and Day 50 – chronic). 
 
Nogo-A expression was examined by in situ 
hybridization in the olfactory bulb, cortex, 
piriform cortex, hippocampus, thalamus, 
cerebellum, brain stem and spinal cord. 
 
Nogo-A and NgR mRNA was quantified 
using semiquantitative RT-PCR using RNA 
extracted from both brain and spinal cord 
tissues. 
 
In situ hybridization and RT-PCR revealed 
that Nogo-A expression is reduced at 
preclinical and acute phases, followed by an 
upregulation during the chronic phase. 
 
Nogo-A mRNA was expressed in neurons and 
oligodendrocytes. 
 
Immunohistochemistry and western blotting 
showed that Nogo-A protein expression was 
increased in the chronic phase and was 
inversely correlated with axonal regeneration 
and axonal injury. 
 
Cortical NgR protein and mRNA levels were 
increased in the chronic phase. 
Theotokis et.al. 
2012 
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Nogo-A and NgR protein expression was 
examined by immunohistochemistry and 
western blotting analyses in brain and spinal 
cord sections. 
 
Double immunofluorescent labeling was 
performed to identify the different types of 
Nogo-A positive cells throughout the different 
EAE time-points. Macrophages were double 
stained with Nogo-A/Mac-3, 
microglia/macrophages were stained with 
Nogo-A/lectin, myelin was stained with 
Nogo-A/CNPase, neurons were stained with 
Nogo-A/NeuN, and astrocytes were stained 
with Nogo-A/GFAP. 
 
Optic Nerve 
Regeneration 
NgR Mouse, NgR knockout mice The abrupt loss of ocular dominance plasticity 
at the end of the critical period, at which the 
cerebral cortex is sensitive to experience-
dependent plasticity, was examined in single 
unit cortical recordings from anesthetized 
mice. 
 
Wisteria floribunda agglutinin-stained sections 
of the visual cortex were examined to assess 
the cellular site of chondroitin sulfate 
proteoglycans (CSPGs). 
 
Homogenates of visual cortex were analyzed 
by western blotting for MBP, NgR, Nogo-A 
and MAG. 
Immunohistochemical layer-specific analysis 
was used to assess MBP expression between 
PN26 and PN60 in NgR knockout mice. 
 
Electrophysiological responsiveness of the 
binocular visual cortex was characterized in 
NgR knockout mice exposed to unmodified 
visual stimuli. 
CSPG-positive perineuronal nets surround 
parvalbumin-positive inhibitory neurons, 
leaving all other neurons unaffected. 
 
Myelin associated proteins including ligands 
for NgR were easily detectable in the postnatal 
visual cortex. The abundance of NgR ligands 
Nogo-A and MAG was consistent in the visual 
cortex over the time course of the critical 
period, whereas NgR tends to increase 
slightly. The total concentration of MBP 
remained nearly constant; however layer-
specific levels of intracortical myelin mature 
considerably as the critical period ends. 
 
The onset and distribution of cortical 
myelination in NgR knockout mice is 
indistinguishable from that of wild-type mice. 
 
NgR and Nogo-A mutant mice are sensitive to 
monocular deprivation after the critical period 
compared to wild-types, as assessed by their 
weighted ocular dominance (WOD) scores. 
McGee AW. et. 
al. 2005 
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Since WOD scores of NgR knockout mice 
were indistinguishable from the wild-type 
mice, visual system development and 
immature cortical plasticity are normal in the 
absence of NgR. 
 
Physiological NgR signaling from myelin-
derived Nogo-A, MAG and OMgp consolidate 
the neural circuitry established during 
experience-dependent plasticity. 
 
Overall, NgR knockout mice display normal 
levels of plasticity during the critical period, 
however it continues abnormally, such that 
ocular dominance at 45 or 120 days postnatal 
is subject to the same plasticity as at juvenile 
ages. 
 
Parkinson’s 
Disease 
Akt Human post-mortem brains 
from Parkinson’s disease 
subjects 
Frozen tissue from the midbrain and paraffin-
embedded sections of substantia nigra pas 
compacta from 5 idiopathic Parkinson’s 
disease cases and 5 controls (matched for age, 
gender, post-mortem delay and tissue pH) 
were obtained from the Netherlands Brain 
Bank. Tissue was dissected using a 
perpendicular cut to the brainstem at the level 
of the superior colliculus. 
 
Western blotting for Akt and phospho
Ser473
-
Akt was performed on fractions prepared from 
midbrain tissue containing the substantia nigra 
pas compacta. 
 
Immunofluorescent microscopy was also 
performed for Akt and phospho
Ser473
-Akt in 
addition to tyrosine hydroxylase. 
 
 
Western blot of midbrain fractions from 
Parkinson’s disease compared to control 
brains showed reduced levels of both total and 
active phospho
Ser473
-Akt in Parkinson’s 
disease. 
Immunofluorescence microscopy of the 
substantia nigra pars compacta confirmed 
these results. 
 
Double immunofluorescence microscopy 
showed that Akt and phospho
Ser473
-Akt are 
expressed at high levels in tyrosine 
hydroxylase immunopositive dopaminergic 
neurons in the control human brain. 
 
Loss of these neurons in Parkinson’s disease 
was accompanied by a marked decrease in Akt 
and phospho
Ser473
-Akt. 
Timmons S. et. al. 
2009 
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Parkinson’s 
Disease 
EGF Rat, Hanover-Wistar (E14 
primary cell cultures from 
ventral mesencephalon) 
E14 embryos were collected from pregnant 
Hanover-Wistar rats and primary cells 
collected from the ventral mesencephalon 
floor were cultured. 
 
Immunostaining on cultured cells was 
performed to differentiate between nuclei of 
proliferating cells, or glial cells from tyrosine 
hydroxylase positive dopaminergic neurons. 
 
Immunohistochemistry using anti-tyrosine 
hydroxylase and anti-heparin-binding 
epidermal growth factor-like growth factor 
(HB-EGF) was performed. 
 
Western blotting using anti-pTyr, anti-
ERK(pT202/pY204), anti-Akt(pS473) and 
anti-Tyr, was performed on ventral 
mesencephalic cells that had been treated with 
HB-EGF for 7 days. 
 
Heparin-binding epidermal growth factor-like 
growth factor (HB-EGF) is expressed in close 
proximity to developing dopaminergic 
neurons. 
 
HB-EGF promotes survival of midbrain 
dopaminergic neurons. 
 
HB-EGF mediates its neuroprotective effects 
via astrocytes. 
 
Endogenous HB-EGF contributes to the 
survival of dopaminergic neurons. 
 
Survival promoting effect of HB-EGF is 
mediated via the EGFR/Akt and MAPK 
signaling pathways. 
Farkas LM. et. al. 
2002 
Parkinson’s 
Disease 
EGF, EGFR, ErbB2 Human post-mortem brains 
from Parkinson’s disease 
subjects 
 
Rat, Wistar 
Post-mortem samples were collected from the 
prefrontal cortex (BA9) and putamen from 9 
chronic Parkinson’s disease brains (4 male, 5 
female) and 10 controls (6 male, 4 female). 
 
Male Wistar rats received intra-nigral 
infusions of 6-hydroxydopamine (2 μL of 4 
mg/mL) or saline under pentobarbital 
anesthesia to induce dopaminergic lesions. 
 
A second group of male Wistar rats received a 
subcutaneous implantation of an osmotic 
minipump filled with human recombinant 
EGF (0.3 mg/mL) or saline, in addition to the 
intra-nigral infusions. These rats were infused 
continuously at a rate of 0.5 μL/h for 7 days. 
 
 
Protein levels of EGF and tyrosine 
hydroxylase were decreased in the prefrontal 
cortex and striatum of patients. 
 
Heparin-binding epidermal growth factor-like 
growth factor (HB-EGF) and transforming 
growth factor alpha (TGF-α) were not 
significantly altered in either region. 
 
EGR receptors (ErbB1, ErbB2 but not ErbB3 
or ErbB4) were downregulated in the same 
forebrain regions. 
 
In the rats treated with nigral 6-
hydroxydopamine infusion to induce 
dopaminergic lesions, the same results were 
replicated. 
 
Iwakura Y. et. al. 
2005 
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Enzyme immunoassays were performed on 
collected brain tissues to determine growth 
factor concentrations. 
 
Protein levels of ErbB family members, 
tyrosine hydroxylase and neuron-specific 
enolase were determined by western blotting. 
 
EGF and ErbB1 were reduced in the striatum 
in the lesioned hemisphere compared to the 
control hemisphere of the treated rats. 
 
Subchronic supplementation of EGF in the 
striatum of the Parkinson’s disease rat model 
was able to locally prevent the dopaminergic 
neurodegeneration as measured by tyrosine 
hydroxylase immunoreactivity. 
 
Parkinson’s 
Disease 
Lingo-1 Human, mixed ethnicity A meta-analysis from 12 case-control studies 
was performed for the Lingo-1 SNP 
rs9652490. 
 
A total of 6053 Parkinson’s disease cases and 
5997 controls, across 4 studies in Asians and 8 
studies in non-Asians were included in the 
meta-analysis. 
 
The meta-analysis showed an overall lack of 
association of rs9652490 and Parkinson’s 
disease. 
 
Separate analysis in subjects of Asian origin 
of non-Asian origin also failed to show any 
ethnic dependent association. 
 
Wu Y. et. al. 2012 
Parkinson’s 
Disease 
Lingo-1 Human, Chinese The Lingo-1 SNP rs9652490 was examined in 
two independent case-control Chinese 
populations involving a total of 1305 subjects 
(649 Parkinson’s disease patients and 656 
controls) from Taiwan and Singapore. 
 
The cohort from Taiwan (421 Parkinson’s 
disease patients and 411 controls) was 
genotyped using TaqMan Assays. 
 
The cohort from Singapore (228 Parkinson’s 
disease patients and 245 controls) was 
genotyped using the Sequenom MassArray 
system. 
 
There were no significant genotypic or allelic 
associations with the risk of Parkinson’s 
disease in either of the two case-control 
populations, nor were there any associations in 
the pooled analysis. 
 
Meta-analysis including all published data to 
date and the present study’s data failed to 
demonstrate any modulatory role of the 
Lingo-1 rs9652490 SNP in Parkinson’s 
disease. 
Wu Y-R. et. al. 
2011 
Parkinson’s 
Disease 
Lingo-1 Human, Caucasian The Lingo-1 SNP rs9652490 was examined in 
a cohort of 162 Polish Parkinson’s disease 
patients (73 females and 89 males) and 177 
controls (81 females and 96 males). All 
subjects were of Caucasian origin. 
Genotyping frequencies were similar in both 
Parkinson’s disease patients and controls. 
 
There were no significant differences in either 
genotypic or allelic frequencies between cases 
Białecka M. et. al. 
2010 
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Genotyping was performed using the 
Sequenom MassArray system 
and controls. 
 
When the Parkinson’s disease group was split 
into early onset and late onset Parkinson’s 
disease, there were still no significant 
differences in genotypic or allelic frequencies 
between case and control groups. 
 
Parkinson’s 
Disease 
Lingo-1, EGFR, 
Akt 
Human post-mortem brains 
from Parkinson’s disease 
subjects 
 
Rat, Sprague-Dawley  
 
Mouse, Lingo-1 knockout 
 
Mouse, C57BL/6 
In situ hybridization and semi-quantitative 
RT-PCR was used to assess levels of Lingo-1 
in the post-mortem human substantia nigra of 
Parkinson’s disease brains compared to age 
matched controls. 
 
Lingo-1 levels were assesses by in situ 
hybridization and/or immunohistochemistry 
on adult rat brains and rat primary in vitro 
embryonic cultures from E15 rat brains. 
The function of Lingo-1 in dopaminergic 
neurons was studied in vitro in the presence of 
Lingo-1 antagonists: Lingo-1-Fc protein, an 
anti-Lingo-1 antibody (1A7) or a dominant-
negative (DN) form of Lingo-1. 
 
Stereotaxic striatal injections of 6- 
hydroxydopamine (6-OHDA) and 
intraperitoneal injections of N-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
were used to create neurotoxin induced 
experimental models of Parkinson’s disease in 
Lingo-1 knockout and wild-type mice. 
 
Lingo-1-Fc protein (6.5 μg/μL; total 2 μL) or 
the Fc-fragment (as a control) was injected 
unilaterally into the striatum of C57BL/6 
mice. Seven days after treatment, mice 
received intraperitoneal injections of MPTP. 
Mice were euthanized 1 week later. 
 
Lingo-1 mRNA levels were found to be 
significantly higher in the substantia nigra of 
Parkinson’s disease patients than controls. 
 
In the ventral midbrain of normal adult rats, 
Lingo-1 mRNA was expressed in many 
neuronal types, and was co-localized with 
tyrosine hydroxylase positive dopaminergic 
neurons. 
 
In primary ventral midbrain cultures, Lingo-1 
protein was also found to be present in 
tyrosine hydroxylase neurons. In the cells 
treated with DN-Lingo-1, 1A7 antibody or 
Lingo-1-Fc, dopaminergic neurons had longer 
neurites than control cultures. Additionally, 
DN-Lingo-1 transduction also resulted in 
increased levels of p-Akt and elevated levels 
of EGFR. 
 
Motor asymmetry was significantly lower in 
6-OHDA treated Lingo-1 knockout compared 
to wild-type mice. 
 
6-OHDA produced a significant loss of 
tyrosine hydroxylase neurons in the substantia 
nigra pars compacta of both wild-type and 
knockout mice; while MPTP resulted in a 
lower number of tyrosine hydroxylase neurons 
in the wild-type compared to Lingo-1 
knockout mice. 
Inoue H. et. al. 
2007 
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EGFR and Lingo-1 interactions were 
examined in cultured cells and wild-type or 
Lingo-1 knockout ventral midbrain tissues 
using co-immunoprecipitation. 
MPTP treated wild-type mice also had lower 
levels of striatal dopamine compared to 
vehicle-treated wild-type mice. Dopamine 
levels were not significantly different in 
vehicle-treated and MPTP-treated Lingo-1 
knockout mice. 
 
There was a higher number of surviving 
tyrosine hydroxylase neurons in the 6-OHDA 
treated Lingo-1 knockout compared to wild-
type mice. There were also increased levels of 
the neuroprotective form of Akt (p-Akt) in the 
ventral midbrain of the MPTP-treated 
knockout compared to wild-type mice. 
 
In the wild-type mice that had received 6-
OHDA treatment, there was a significantly 
higher level of Lingo-1 protein in the striatum 
3 days after injury. 
 
Lingo-1-Fc treatment resulted in unilateral 
increase in the number of tyrosine 
hydroxylase neurons, and in dopamine levels 
in the substantia nigra pars compacta. 
 
Lingo-1 decreases EGFR protein levels in a 
dose-dependent manner. The anti-Lingo-1 
antibody 1A7 blocked the binding of Lingo-1 
to EGFR. EGFR activation was suppressed by 
Lingo-1, and the 1A7 antibody was able to 
attenuate these effects; therefore Lingo-1 can 
reduce EGFR levels by direct physical 
interaction. 
 
Schizophrenia, 
Major 
Depressive 
Disorder, 
Bipolar 
BDNF, TrkB, p75 Human post-mortem brains 
from schizophrenia, major 
depressive disorder and 
bipolar disorder subjects 
Post-mortem anterior hippocampal and 
cerebellum brain samples were obtained from 
the Stanley Foundation Neuropathology 
Consortium. The cohort consisted of 15 
schizophrenia subjects, 15 major depressive 
Reductions in BDNF were seen in all layers of 
the right but not left hippocampus in major 
depressive disorder patients, with no changes 
in the dentate gyrus. 
 
Dunham JS. et. al. 
2009 
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Disorder disorder subjects, 15 bipolar disorder subjects 
and 13 age and gender matched controls. 
 
Protein levels of BDNF, TrkB and p75 were 
assessed in the hippocampal samples by 
western blotting and immunoautoradiography. 
 
Genomic DNA was extracted from the 
cerebellum samples from each subject, and 
genotyping was performed using the 
Sequenom iPLEX platform, for several SNPs 
located in the BDNF, NTRK2 and NGFR 
genes (full list not disclosed). 
A similar but less pronounced pattern was 
observed for bipolar disorder.  
 
Bipolar, but not major depressive patients had 
bilateral reductions in p75 in hippocampal 
layers, but not in the dentate gyrus. 
No changes in TrkB were seen in any 
diagnosis. 
 
BDNF density was reduced in subjects who 
carried the minor allele for rs12273363 and 
rs7127505. 
 
TrkB density was decreased in subjects who 
carried the minor allele for rs1187323 and 
rs1187326. 
 
p75 density was increased in subjects who 
carried the minor allele for rs11466117. 
 
Schizophrenia EGFR Human post-mortem brains 
from schizophrenia subjects 
Post-mortem brain samples from the 
dorsolateral prefrontal cortex (BA46) were 
obtained from 37 schizophrenia subjects and 
37 matched controls. 
 
EGFR mRNA expression was assessed by in 
situ hybridization and quantitative real-time 
PCR.  
 
Protein levels were assessed by western 
blotting 
Increased EGFR protein was seen in the 
dorsolateral prefrontal cortex of schizophrenia 
subjects compared to controls. 
 
There were no significant differences in 
mRNA levels between patients and controls. 
 
Protein levels were significantly correlated 
with mRNA levels in both the schizophrenia 
group and in the control group. 
 
Subjects with no history of suicidality had 
significantly higher levels of EGFR protein 
and mRNA compared to those with 
suicidality. 
 
Swaminathan V. 
et. al. 2014 
Schizophrenia Lingo-1, NgR, p75, 
TROY, WNK1, 
Myt1 
Human post-mortem brains 
from schizophrenia subjects 
Post-mortem brain samples from the 
dorsolateral prefrontal cortex (BA46) were 
obtained from 37 schizophrenia subjects and 
Significant increases in Lingo-1 and Myt1 
were observed in the DLPFC of schizophrenia 
brains compared to controls. Additionally, a 
Fernandez-
Enright F. et. al. 
2014 
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37 matched controls. Samples were taken 
from the middle one-third (rostro-caudally) of 
the middle frontal gyrus from coronal slabs 
anterior to the genu of the corpus callosum. 
 
Post-mortem brain samples from the 
hippocampus (CA1 and CA3 regions), taken 
from the level of the lateral geniculate nucleus 
were obtained from 20 schizophrenia subjects 
and 20 matched controls from the same cohort 
as the DLPFC samples. 
 
 
Protein levels for Lingo-1, NgR, p75, TROY, 
WNK1, Myt1 and MBP were assessed by 
western blotting in all 3 brain regions. 
 
significant decrease in NgR was observed in 
the same region. 
 
Both TROY and WNK1 were significantly 
increased in the CA1 hippocampal region in 
schizophrenia compared to control subjects. 
 
NgR was significantly increased in the CA3 of 
schizophrenia subjects compared to controls. 
 
No significant changes in MBP levels were 
reported in any brain region. 
 
Confounding factors had no impact on levels 
of protein expression.  
 
Schizophrenia Myt1l Human, Chinese Genomic DNA samples were collected from 
528 paranoid schizophrenia patients (264 
males and 264 females (mean age 27.32±8.03 
years)) and 528 healthy controls (264 males 
and 264 females (mean age 27.73±8.01 
years)). 
 
Genotyping was performed for 6 SNPs in the 
Myt1l gene (rs17039584, rs10190125, 
rs17338616, rs10432710, rs6742365, 
rs2385135) using the Illumina GoldenGate 
assay on a BeadStation 500G Genotyping 
System. 
 
The SNP rs17039584 was significantly 
associated with schizophrenia, even after 
Bonferroni correction. 
 
The SNP rs10190125 was found to be 
significantly associated with schizophrenia in 
female patients. 
 
The SNP rs6742365 was associated with a 
family history of schizophrenia in females. 
Li W. et. al. 2012 
Schizophrenia Myt1l Human, Caucasian A genome-wide screen for copy number 
variations was performed on a small cohort of 
54 Dutch schizophrenia subjects, using an 
Affymetrix GeneChip 250K SNP array. 
 
4 of the novel copy number variations were 
chosen based on their gene content for further 
validation by multiplex ligation-dependent 
A total of 90 copy number variations were 
identified, 77 of which had previously been 
reported in unaffected control cohorts. 
 
13 novel copy number variations were 
identified in this study, of which 7 did not 
affect any gene, nor were they located in 
highly conserved regions. 
Vrijenhoek T. et. 
al. 2008 
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probe amplification or genomic quantitative 
PCR. 
 
The second part of this study involved 
studying copy number variations within the 4 
loci in a large Dutch case control cohort 
consisting of 752 schizophrenia subjects and 
706 unaffected controls. 
The four copy number variations validated 
included 2 duplications in chromosomal 
regions 2p25.3 (affecting 4 genes – including 
Myt1l) and 5p15.2 (affecting 7 genes), and 2 
deletions in chromosomal regions 2p16.3 
(affecting the NRXN1 gene) and 9q33.1 
(affecting the ASTN2 gene). 
 
Within the larger cohort, an additional 8 copy 
number variations were identified (7 in 
patients and 1 in a control subject). The 4 
variations that affect coding sequences were 
found only in the patient cohort, including 1 
previously unreported copy number variation 
at 2p25.3, a 3.8 Mb duplication affecting 11 
genes including Myt1l. 
 
Schizophrenia Myt1 Human post-mortem brains 
from schizophrenia subjects 
Post-mortem hippocampal and cerebellar 
tissue was collected from 44 schizophrenia 
patients (29 males and 15 females; of which 
24 were African American and 20 were 
Caucasian), and 84 normal controls (62 males 
and 22 females; of which 53 were African 
American, 25 were American Caucasian, 5 
were Hispanic and 1 was Asian). Subjects 
were matched for age, brain pH and post-
mortem interval. 
 
Hippocampal Neuregulin1 (NRG1) mRNA 
expression was measured by quantitative RT-
PCR using an ABI Prism 7900 sequence 
detection system with 384-well format. 
 
Genomic DNA was extracted from cerebellar 
tissue. A total of 10 SNPs within NRG1 were 
genotyped; 4 from the de-CODE core 
haplotype (SNP8NRG221132, 
SNP8NRG221533, SNP8NRG241930 and 
SNP8NRG243177) and 6 additional SNPs 
NRG1 type I mRNA expression levels were 
increased in the hippocampus of schizophrenia 
patients compared to controls. No significant 
differences were observed for any of the other 
NRG1 isoforms. 
 
None of the SNPs examined showed any 
effect on the expression of type II or type III 
NRG1 isoforms. 
 
There was a genotype x diagnosis interaction 
for SNP8NRG221132 and type I NRG1 
mRNA expression; however there was no 
main effect of genotype. 
 
There was a significant main effect of 
SNP8NRG243177 on type IV NRG1 
expression.  
 
Individuals heterozygous for the (T) risk allele 
in SNP8NRG243177 have 21% more type IV 
NRG1 mRNA than those individuals 
Law AJ. et. al. 
2006 
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from HAPMAP (rs10096573, rs4268090, 
rs4298458, rs4452759, rs4733263 and 
rs4476964). Genotyping was performed using 
the TaqMan 5’ exonuclease allelic 
discrimination assay. 
 
Putative transcription factor binding site 
analysis was performed using 
MATINSPECTOR software, a computational 
suite for promoter informatics. 
homozygous for the (C) major allele. 
 
Individuals homozygous for the (T) risk allele 
in SNP8NRG243177 have 49% more type IV 
NRG1 mRNA than those individuals 
homozygous for the (C) major allele. 
 
This effect appeared more pronounced in the 
schizophrenia group, despite no diagnosis x 
genotype interaction being present. 
 
The SNP8NRG243177 was found to be within 
a putative binding site for serum response 
factor (SRF) and myelin transcription factor 1 
(Myt1). Carrying the risk (T) allele results in a 
predicted loss of binding to both of these 
transcription factors. 
 
The SNP8NRG243177 variant was found to 
be within a predicted transcription factor 
binding domain for SRF, with the risk (G) 
allele abolishing SRF binding. 
 
Schizophrenia NgR Human A total of 695 patients with schizophrenia, 
schizoaffective disorder or schizophreniform 
disorder were screened for 22q11 interstitial 
deletions. 
 
A separate study consisting of 18 velocardial 
facial syndrome patients, of which 4 also had 
schizophrenia, were screened to test they 
hypothesis that a more extensive deletion may 
be present in the subgroup of velocardial 
facial syndrome patients who also have a 
diagnosis of schizophrenia. 
 
 
2 deletions were identified and characterized 
by fluorescence in situ hybridization. Both 
were hemizygously deleted for cosmids N25 
(D22S75) and DO832 (D22S502). 
 
No correlation exists between the extent of the 
deletion and the additional schizophrenia 
phenotype; however the prevalence of 
schizophrenia in this small sample (22%) is 
much higher than that of the general 
population (1%). 
Karayiorgou M. 
et. al. 1995 
Schizophrenia NgR, Nogo-A Human, mixed ethnicities 
 
The case control cohort for SNP genotyping 
consisted of 636 Caucasians (336 
rs701428 was found to be weakly associated 
with schizophrenia, with the minor allele 
Budel S. et. al. 
2008 
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Cells, E7 chick retinal 
explants 
 
Cells, E13 chick dorsal root 
ganglion (DRG) explants 
 
Cells, dissociated E20 rat 
DRG cultures 
 
Mouse, NgR knockout 
schizophrenia and 300 controls) and 296 
African Americans (196 schizophrenia and 
100 controls). DNA was also obtained from 
1122 Chinese Trios (621 schizophrenia 
patients and 501 controls). 
 
A total of 7 SNPs in the NgR gene (rs701421, 
rs701428, rs1567871, rs696880, rs854927, 
rs9606296 and rs701427) were genotyped 
using a TaqMan SNP Genotyping Assay. 
 
DNA from a separate cohort of 542 
schizophrenia probands and NgR variant 
pedigrees, along with 650 healthy controls 
were obtained for DNA sequencing. 
The entire translated region, plus approx. 500 
bp of the 5’ and 3’ untranslated region was 
sequenced. 
 
E7 chick retinal explants and E13 chick DRG 
cells (expressing wild type NgR or the novel 
NgR variants) were used for growth cone 
collapse experiments. 
 
E20 rat DRG cultures were used for neurite 
outgrowth experiments. 
 
Cognitive assessment in NgR knockout and 
wild-type mice was assessed in the spatial 
delayed alternation task. 
 
NgR knockout and wild-type mice also 
underwent prepulse inhibition testing. 
 
enriched in the Caucasian group. 
4 novel missense variations were identified in 
the cohort of 542 schizophrenia probands 
(R377W, R377Q, R227C and R399W), with 3 
of the 4 novel variants predicted to disrupt 
protein function (R377W, R227C and 
R399W). While R377Q and R377W are not 
within the ligand-binding domain, they are in 
the region of the protein that is required for 
signal transduction, and may disrupt signaling. 
 
Wild-type NgR sensitizes E7 chick retinal 
explants to Nogo-A, whereas the R377Q or 
R377W variants do not. Similarly MAG-
mediated inhibition of neurite outgrowth in 
E20 rat DRG neurons is supported by wild-
type NgR but not by the NgR R377 variant. 
 
E13 chick DRG neurons express NgR and are 
responsive to Nogo-A, whereas R377Q and 
R377W substituted proteins block the function 
of the endogenous NgR and function as 
dominant negatives. 
 
NgR knockout mice have impaired working 
memory in the spatial delayed alternation task. 
 
A small subset of NgR knockout mice exhibit 
decreased prepulse inhibition. 
 
Schizophrenia NgR Human, Caucasian Genomic DNA from a total of 120 unrelated 
schizophrenia patients (77 males and 43 
females) and 300 controls (180 males and 120 
females) were screened for mutations in the 
NgR gene using denaturing high performance 
3 mutant alleles were detected in the 
schizophrenia patients. 2 were missense 
mutations and 1 was a synonymous codon 
variant. 
 
Sinibaldi L. et. al. 
2004 
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liquid chromatography. 
All subjects were of Italian origin. 
 
The crystallographic structure of NgR was 
used to evaluate the functional relevance of 
the R119W and R196H mutations. 
1 patient was heterozygous for a cytosine to 
thymine transition resulting in an arginine to 
tryptophan substitution (R119W). This 
mutation is located in the 3
rd
 leucine-rich 
repeat which is expected to be an important 
functional domain. 
 
Another patient was heterozygous for a 
guanine to adenine transition resulting in an 
arginine to histidine substitution (R196H). 
This mutation is located in the 6
th
 leucine-rich 
repeat. 
 
These change mutations were not found in any 
of the 600 control chromosomes. 
 
Both of the missense mutations were predicted 
to alter the electrostatic binding properties of 
NgR, and may result in alterations in the 
function and/or stability of the NgR, possibly 
affecting its ability to bind to other 
components of the receptor complex (p75 and 
Lingo-1). 
 
The patient with R119W mutation suffered 
deficit syndrome schizophrenia, while the 
patient with R196H suffered early onset and 
disorganized schizophrenia. The negative 
symptoms of both patients were strongly 
resistant to both conventional and novel drug 
treatments. 
 
Schizophrenia WNK1 Human Microarray technology by Affymetrix was 
used to determine the expression of over 
30,000 mRNA transcripts in the post-mortem 
anterior prefrontal cortex (BA 10) in 28 
schizophrenia and 23 control brains collected 
from Charing Cross Hospital. 
 
A total of 51 gene expression changes were 
common to both groups of schizophrenia 
patients, and of these changes, 49 of them 
showed the same direction of disease-
associated regulation. 
 
WNK1 was shown to be upregulated in both 
Maycox PR. et. 
al. 2009 
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The results of this study were then compared 
to an independent dataset acquired from the 
prefrontal cortex (BA 9) of 16 schizophrenia, 
and 27 control brains, collected from the 
Harvard Brain Bank. 
 
prefrontal cortical regions of the post-mortem 
schizophrenia brain from both the Charing 
Cross and the Harvard Brain Bank cohorts. 
Spinal Cord 
Injury 
Lingo-1 Rat, Sprague-Dawley 
 
Rat, Long Evans 
ELISA competition assay was used to 
determine if Lingo-1-Fc can inhibit Lingo-1 
binding to NgR. 
 
Sprague-Dawley rats underwent a lateral 
hemisection procedure at cervical vertebra C7, 
to completely interrupt the rubrospinal tract 
components. Long-1-Fc was administered 
locally using a gel foam sponge soaked with 
20 μg/10 μL Lingo-1-Fc protein placed at the 
site of injury. 
 
Long Evans rats underwent a dorsal 
hemisection procedure at thoracic vertebra T7 
to completely interrupt the main dorsomedial 
and the dorsolateral corticospinal tracts. An 
intrathecal catheter was inserted into the 
subarachnoid space at T7 and a mini-osmotic 
pump delivered Human Lingo-1-Fc fusion 
protein (25 μM), Human IgG isotype control 
protein (5 mg/mL) or PBS at a rate of 0.25 
μL/h. 
 
Functional recovery, RhoA activation and 
histological analyses were performed to assess 
the effectiveness of the Lingo-1-Fc treatment 
following spinal cord injury. 
 
Lingo-1-Fc significantly decreased the 
binding of Lingo-1 to NgR. 
 
Lingo-1-Fc treatment significantly improved 
both forelimb and hindlimb functional 
recovery, promoted axonal sprouting and 
decreased RhoA activation in both dorsal and 
lateral hemisection models. 
 
Lingo-1-Fc treatment also increased 
oligodendrocyte and neuronal survival after 
either rubrospinal or corticospinal tract 
transection. 
Ji B. et. al. 2006 
Spinal Cord 
Injury 
Lingo-1 Rat, Long Evans 
 
Primary cell culture, 
cerebellar granular neurons 
from P7 rats 
Long Evans rats underwent a dorsal 
laminectomy procedure at thoracic level T6 
and T7. A dorsal hemisection was performed 
to completely disrupt the main dorsomedial 
and the minor dorsolateral corticospinal tracts. 
In situ hybridization and 
immunohistochemistry showed that Lingo-1 is 
expressed in neurons. 
 
Lingo-1 mRNA was detected in PN2, PN4 
Mi S. et. al. 2004 
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Cells, COS-7  
Rats were euthanized and tissues were 
collected for Lingo-1 expression analysis. 
 
RT-PCR was used to quantify Lingo-1 mRNA 
levels in rat brains and injured spinal cords. 
 
In situ hybridization was used to detect Lingo-
1 mRNA in rat brain, spinal cord and dorsal 
root ganglia. 
 
Primary cerebellar granular neurons were 
cultured from P7 rats, and were seeded onto 
slides pre-coated with OMgp-Fc, Nogo-66-
GST, myelin, Lingo-1-Fc, or control-Fc. 
 
Immunohistochemistry was used to detect 
levels of Lingo-1, NgR and p75 in rat brain 
sections and PN7 rat cerebellar granular 
neurons. 
A separate lot of cerebellar granular neurons 
were transfected with dominant negative 
(DN)-Lingo-1, and vector control. DN-Lingo-1 
expression in the cells was verified by western 
blotting. 
 
COS-7 cells transfected with Lingo-1, NgR 
and p75 were immunoprecipitated and 
analyzed by western blotting. 
 
COS-7 cells were transfected with NgR and 
p75, or with NgR, p75 and Lingo-1, and 
analyzed for alkaline phosphatase (AP)-
OMgp, AP-Nogo or AP-Lingo-1 binding by 
ELISA. 
 
GTP-bound and total RhoA proteins were 
detected in Lingo-1-, p75-, and NgR- 
transfected COS-7 cells by western blotting. 
 
and PN8 cultured cerebellar granular neurons. 
 
Immunohistochemistry revealed that Lingo-1 
expression was higher in the PN7 cerebellar 
granular neurons than in the corresponding 
adult tissue. 
 
Immunohistochemistry also showed that 
Lingo-1 was detected in rat spinal cord axonal 
tracts following injury. 
 
Quantitative RT-PCR showed that Lingo-1 
was increased 5-fold 14 days following injury. 
 
COS-7 cell culture experiments showed that 
Lingo-1 and NgR are able to bind to each 
other. 
 
RhoA activation in Lingo-1-, p75-, and NgR- 
transfected COS-7 cells showed that Lingo-1, 
NgR and p75 can together mediate the 
inhibitory activities of myelin. 
 
DN-Lingo-1 transfected neurons showed 
diminished responses to inhibitory substrates, 
evidenced by the presence of longer neurites 
than the cells transfected with the control 
vector. 
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Spinal Cord 
Injury 
NgR Mouse, NgR knockout NgR knockout mice were generated from 
C57BL/6J mice. 
 
NgR knockout and wild-type mice were 
subjected to open field testing for locomotor 
activity and rotarod testing for motor 
coordination and learning. 
 
Myelin inhibitory proteins Nogo-A, MAG 
OMgp and CNS myelin were examined for 
growth cone collapsing activity in wild-type 
versus NgR knockout PN14 DRG cultures. 
 
Mice underwent a dorsal laminectomy 
procedure at thoracic level T6 and T7. A 
dorsal hemisection was performed at T6 to 
completely disrupt the dorsal and dorsolateral 
corticospinal tracts. Complete transections 
were performed at T8. 
 
The corticospinal and rubrospinal tracts were 
traced with injections of biotin dextran amine 
(BDA). 
 
Locomotor recovery in NgR knockout versus 
wild-type mice following a midthoracic dorsal 
hemisection injury was assessed by open field 
testing. 
 
NgR knockout mice display hypoactivity and 
motor impairment. 
 
DRG neurons lacking NgR do not bind Nogo-
A, and their growth cones are not collapsed by 
Nogo-A. 
 
Recovery of motor function after dorsal 
hemisection of the spinal cord is improved in 
NgR knockout mice. 
 
Corticospinal fibers do not recover in NgR 
knockout mice after hemisection; however 
some raphespinal and rubrospinal fibers do 
regenerate. 
Kim JE. et. al. 
2004 
Spinal Cord 
Injury 
Lingo-1, NgR, p75, 
TROY 
Mouse, BALB/c Distribution and intensity of mRNA signal 
and immunoreactivity for receptors of myelin 
associated inhibitors was assessed by in situ 
hybridization for NgR, Lingo-1, p75 and 
TROY, and immunohistochemistry for p75. 
 
Neuronal cell groups that project into the 
spinal cord and express one or more of the 
receptors for myelin inhibition were examined 
using co-localization of in situ hybridization 
In situ hybridization, immunohistochemistry 
and neuronal tracing revealed that NgR and 
Lingo-1 are strongly expressed in several 
neuronal populations of the adult mouse brain 
projecting into the spinal cord, including: the 
corticospinal, reticulospinal, raphespinal and 
vestibulospinal tracts. 
 
p75 expression was restricted to the neuronal 
populations in the descending pathways from 
Barrette et. al. 
2007 
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or immunofluorescence labeling of the 
neuronal tracer Fluoro-Gold (FG) injected into 
the thoracic spinal cord. 
 
Spinal cord sections were stained with an anti-
glial fibrillary acid protein (GFAP, a marker 
of astrocytes) antibody, Luxol fast blue 
(LFB)/cresyl violet (CV) and FluoroJade B 
(FJB), to examine the extent of tissue loss and 
axonal damage in mice subjected severe spinal 
cord contusions. 
the brainstem. TROY was absent from most 
brain regions and from all neuronal projection 
systems. 
 
In the mice that underwent severe spinal cord 
contusions, GFAP astrocytes accumulated 
around the site of the injury forming a glial 
scar. 3D spinal cord reconstructions and 
labeling with FJB revealed that axons from 
several projection systems were injured. 
 
Quantitative analysis of in situ hybridization 
signals for receptors of myelin associated 
inhibitors revealed no significant difference in 
average number of positive cells and 
hybridization signal per cell between naïve 
and spinal cord injury mice. There was also no 
change in the expression profile of receptors 
for myelin associated inhibitors over time 
post-spinal cord injury. 
 
Spinal Cord 
Injury 
TROY Chinese Hamster Ovary 
(CHO) cells 
 
Cells, COS-7 
 
Mouse, TAJ knockout 
 
Primary cell culture, PN7 
cerebellar granular neurons 
and dorsal root ganglion 
(DRG) neurons from TAJ 
knockout mice 
CHO cells at 90% confluence were transfected 
with various combinations of human NgR, rat 
p75, and human Lingo-1 constructs. 
 
ELISA plates coated with soluble NgR were 
incubated with serial dilutions of alkaline 
phosphatase (AP)-TAJ, AP-p75 or control-AP 
to quantify bound AP-TAJ. 
 
COS-7 cells were transfected with 
combinations of full-length human TAJ, 
human NgR, human Lingo-1 and rat p75. 
Western blotting was used to assess levels of 
NgR, Lingo-1 and TAJ/TROY. 
 
Quantitative RT-PCR was performed for TAJ, 
p75, NgR, and Lingo-1 on whole mouse brain 
homogenates taken over a developmental 
AP-TAJ was found to bind to cells which 
expressed NgR, NgR/Lingo-1 and 
NgR/Lingo-1/p75, but not to vector 
transfected cells or CHO cells expressing only 
p75 or Lingo-1. 
 
TAJ binds to NgR and can replace p75 in the 
p75/NgR/Lingo-1 complex to activate RhoA 
in the presence of myelin inhibitors. 
 
TAJ and p75 showed differential expression 
patterns in the rat brain across developmental 
time-points, with p75 expression peaking at 
E14 and E18 but dropping into adulthood. TAJ 
was expressed at its highest between PN0-
PN8. Higher levels of TAJ were observed in 
PN23 and adult samples compared to 
expression of p75. Levels of Lingo-1 and NgR 
Shao et. al. 2007 
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time-course (embryonic day E14 and E18, and 
postnatal day PN0, PN4, PN8, PN23 and adult 
brains). 
 
COS-7 cells were transfected with various 
combinations of TAJ, NgR, and Lingo-1. The 
cells were subsequently treated with AP-
OMgp, GST-Nogo-66, MAG-Fc or control. 
Western blotting was then used to assess for 
levels of RhoA in the various cells. 
 
Cerebellar granular neurons and DRG neurons 
from TAJ knockout mice were assessed for 
neurite outgrowth in vitro. 
 
mRNA resembled those of TAJ, with highest 
expression being at PN4 and declining slowly 
into adulthood. 
 
In vitro exogenously added soluble TAJ 
reversed neurite outgrowth in normal 
cerebellar granular neurons and DRG neurons 
caused by myelin-associated inhibitor factors 
MAG, OMgp and Nogo. 
 
Neurons from TAJ knockout mice were more 
resistant to the suppressive action of the 
myelin inhibitors. 
Stress and 
Depression 
Akt, BDNF, TrkB Rat, Sprague-Dawley 
 
Mouse, C57BL/6 
 
Mouse, CD1 retired breeders 
 
Human, post-mortem brains 
from depressed subjects 
Chronic fluoxetine was administered via 
subcutaneous implants of pellets in the dorsal 
interscapular region. The pellets delivered 20 
mg/kg/day of fluoxetine or placebo over a 20-
day interval. 
 
C57BL/6 mice were subjected to a social 
defeat paradigm using resident CD1 mice as 
the aggressors. 
 
Samples from post-mortem human ventral 
tegmental area and both the ventral tegmental 
area and nucleus accumbens from the 
C57BL/6 mice were used in western blotting 
assays for Akt, phospho-Akt, BDNF, and 
TrkB. 
 
 
Susceptibility to social defeat was associated 
with a significant reduction in levels of 
active/phosphorylated Akt within the ventral 
tegmental area. 
 
Chronic antidepressant treatment in both mice 
and humans resulted in increased active Akt 
levels. 
 
Defeat induced reduction in Akt activation in 
susceptible mice was necessary and sufficient 
to induce depressive behaviors associated with 
susceptibility. 
 
Pharmacological reductions in Akt resulted in 
a significant rise in the firing frequency of 
ventral tegmental area dopamine neurons. 
 
Krishnan V. et. al. 
2008 
Traumatic Brain 
Injury 
MAG Rat, Sprague-Dawley Adult male rats were subjected to either lateral 
fluid percussion brain injury or sham injury. 
 
Treatment with either 8.64 μg anti-MAG 
monoclonal antibody or IgG control antibody, 
delivered by osmotic minipumps, began 1 
At 72 hours post-injury, rats showed increased 
immunoreactivity for MAG in the ipsilateral 
cortex, thalamus and hippocampus of brain 
injured animals; anti-MAG was detected in 
the hippocampus, fimbria and ventricles. 
 
Thompson HJ. et. 
al. 2006 
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hour post injury and continued for 72 hours. 
 
One group of rats was euthanized at the 72 
hour post injury time-point to verify drug 
diffusion and MAG immunohistochemistry. 
 
All other rats were evaluated for up to 8 weeks 
post-injury to assess neurologic motor, 
sensory and cognitive function using a battery 
of previously described tests, including but not 
limited to the rotarod test, adhesive paper test, 
and Morris water maze test. 
 
Hemispheric tissue loss was evaluated at 8 
weeks post-injury. 
 
Brain-injured rats that received anti-MAG 
antibody treatment showed significantly 
improved recovery of sensorimotor function at 
6 and 8 weeks post-injury compared to the 
brain-injured IgG control treated rats. 
 
8 weeks post-injury, anti-MAG treated brain-
injured rats showed significantly improved 
cognitive function and reduced hemispheric 
tissue loss compared to brain-injured controls. 
Traumatic Brain 
Injury and 
Epilepsy 
RhoA Rat, Sprague-Dawley Male rats were subjected to a lateral fluid 
percussion brain injury; cortex and 
hippocampus from both hemispheres were 
collected 24 h to 3 days after injury. 
 
A second set of male rats were administered 
kainic acid (10 mg/kg i.p.) to induce seizure; 
brains were collected 24 h after injections and 
bilateral hippocampi were removed. 
 
GTP-RhoA pull down assays were performed 
on rat cortical and hippocampal tissue 
homogenates. 
 
RhoA activation was increased from 24 h to 3 
days post-injury in the cortex, and by 3 days 
in the hippocampus, ipsilateral to the injury.  
 
RhoA activation was also detected in the 
cortex and hippocampus contralateral to the 
injury, without alterations in the level of 
RhoA. 
 
Severe seizures resulted in bilateral RhoA 
activation in cortex and hippocampus. 
Dubreuil CI. et. 
al. 2006 
Traumatic Brain 
Injury 
RhoA Human, post-mortem brains 
from traumatic brain injury 
subjects 
The post-mortem cohort consisted of brains 
from 25 patients who died after various 
survival times following closed traumatic 
brain injury, in addition to 4 brains of 
neuropathologically normal cases used as 
controls. 
 
Immunohistochemistry was used to detect 
RhoA expression throughout the brain at 
The main cellular sources of RhoA after 
traumatic brain injury were 
monocytes/macrophages, granulocytes and 
neurons. 
 
Following closed traumatic brain injury there 
was a significant increase in the number of 
parenchymal cells expressing RhoA at the 
lesion site, but not in neighboring areas. 
Barabeck C. et. al. 
2004 
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different stages of survival (<7 hours, 12-48 
hours, 4-16 days, and months) following 
closed traumatic brain injury. 
 
There were no significant differences in the 
number of RhoA positive cells in the very 
early stages following injury (<7 hours); 
RhoA expression was confined to shrunken 
eosinophilic neurons. 
RhoA expression was highest between 1-2 
weeks post injury and was predominantly 
expressed in macrophages at this stage post-
injury. 
 
In the later stages post-injury (months), 
additional staining was observed in reactive 
astrocytes. 
 
Tuberous 
Sclerosis & 
Cortical 
Dysplasia 
Nogo-A Human, surgical specimens 
from pediatric patients 
undergoing surgery for 
epilepsy. 
Brain biopsy specimens were used to examine 
the expression patterns of the Nogo-A system 
in cortical lesions of 28 pediatric patients with 
tuberous sclerosis complex (TSC) (n=16) and 
focal cortical dysplasia type IIb (FCDIIb) 
(n=12). Control white matter cortical 
specimens were obtained from the brains of 10 
normal-appearing brains of pediatric patients 
without a history of seizures or other 
neurological disorders at autopsy. 
 
Western blotting and immunohistochemistry 
were used to examine expression levels of 
Nogo-A, NgR, Lingo-1, TROY, p75 and 
RhoA in the brain specimens of FCDIIb, TSC 
and control subjects. 
 
Quantitative RT-PCR was used to examine 
relative levels of Nogo-A and NgR mRNA in 
all samples. 
 
mRNA and protein levels of Nogo-A, NgR, 
Lingo-1, TROY and RhoA, but not p75 were 
upregulated in the cortices of patients 
compared to autopsy controls. 
 
Immunohistochemistry showed that Nogo-A 
and NgR were expressed strongly in 
misshapen cells, particularly in dysmorphic 
neurons, balloon cells and giant cells. 
 
TROY was diffusely expressed in the 
malformations of cortical development. 
 
The majority of Nogo-A/NgR positive cells 
were co-labeled with neuronal rather than 
astrocytic markers.  
Yu S-X. et. al. 
2012 
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oligodendrocyte precursor cell; p75: p75 neurotrophin receptor; PCR: polymerase chain reaction; Phospho: phosphorylated; PI3-K: phosphatidylinositide 3-kinase; PN: 
postnatal day; RGC: retinal ganglion cell; RhoA: ras homolog gene family, member A; RNAi: RNA interference; RT-PCR: real-time polymerase chain reaction; SHR: 
spontaneously hypertensive rats; SNP: single nucleotide polymorphism; SRF: serum response factor; TAJ: TNF receptor orphan Y (TROY); tcTPC: time-controlled 
transcardiac perfusion cross-linking; TNFRSF19: Tumor necrosis factor receptor superfamily, member 19 (TROY); TrkB: tropomyosin receptor kinase B; TROY: TNF 
receptor orphan Y; TSC: tuberous sclerosis complex; VPA: Valproic acid; WNK1: WNK lysine deficient protein kinase 1; WOD: weighted ocular dominance. 
 
 
